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1. INTRODUCTION 
 
Ca2+ ions play crucially important roles in regulating a variety of cellular functions. They 
provide the basis for excitability in nerve and muscle cells. In neurons, they trigger the 
release of neurotransmitters from nerve the terminal. In heart and skeletal muscle, they 
regulate excitability and transform the action potential in mechanical contraction. In 
addition, Ca2+ ions are involved in a broad range of cell regulatory processes – e.g. hormone 
secretion and volume regulation, gene expression and mediating cell death. Several 
hereditary diseases have been linked to mutations in genes encoding ion channels. Timothy’s 
syndrome [1], which is a novel disorder characterized by multiorgan dysfunction including 
lethal arrhythmias, webbing of fingers and toes, congenital heart disease, immune 
deficiency, intermittent hypoglycemia, cognitive abnormalities, and autism. In every case, 
Timothy syndrome results from the identical, de novo CaV1.2 missense mutation G406R in 
exon 8a. CaV1.2 is expressed in all affected tissues. Functional expression reveals that 
G406R produces maintained inward Ca2+ currents by causing nearly complete loss of voltage-
dependent channel inactivation. This likely induces intracellular Ca2+ overload in multiple cell 
types. In the heart, prolonged Ca2+ current delays cardiomyocyte repolarization and 
increases risk of arrhythmia, the ultimate cause of death in this disorder. These 
discoveries establish the importance of CaV1.2 in human physiology and development and 
implicate Ca2+ signaling in autism. Molecular electrophysiological investigation of these so-
called channelopathies elucidate the pathophysiology of these rare diseases and help to 
understand disease-causing mechanisms in other, more common disorders with similar 
symptoms. Furthermore, insight into the molecular basis of these disorders allows a more 
rational approach to therapy. On the other hand, disease-causing mutations point to 
functional important parts of the protein and help to understand ion channel gating on a 
molecular level. 
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1.1. Cardiac L-VDCC Structure 
The L-VDCCs are heterotetrameric polypeptide complexes comprised of the α1, α2/δ, and β 
(and in some tissues γ) subunits (See Figure 1 [2]) that allow depolarization-induced calcium 
influx into the cytosol. In all excitable tissues, Ca2+ channels invariably contain α1, α2/δ, and 
β subunits. These are considered the functional minimum “core” for Ca2+ channel assembly. 
The accessory subunits (β, α2/δ) are tightly, but not covalently, bound to the α1 subunit 
and modulate the biophysical properties and trafficking of the α1 subunit to the membrane. 
The stoichiometric ratio between the α1,α2/δ and the β2 subunits is 1:1:1 [3]. 
Figure 1. Structural organization of L-VDCC. Sites of interaction between subunits are indicated. The numbers 
point to areas found to be important to specific channel functions. The EF hand, A, c, and IQ motifs represent 
specific peptide sequences involved in CaM binding. Key amino acids required for Ca2+ antagonist binding are 
represented in red letters. At least 5 consensus sites for phosphorylation by cAMP-dependent PKA have been 
discovered within the C-terminal tail of α1C. AKAP79 (79 kDa A-kinase-anchoring protein) helps to target PKA to 
its specific substrate. COOH, carboxy-terminal.  
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1.1.1. α1 subunits 
The founding members of this superfamily are the voltage-gated sodium channels (Na+). The 
Ca2+ channel α1 subunit (170-240 kDa) consists of four homologous motifs (I-IV) each 
composed of six membrane-spanning α-helices (termed S1 to S6) linked by variable 
cytoplasmic loops (linkers) between the S6 and S1 segments. The different types of α1-
subunits differ most strikingly in two principal regions: the cytoplasmic loop linking motifs 
II and III and the carboxy-terminal region. The currents that are supplied by the voltage-
dependent calcium channels (VDCCs) are called: L-, N-, P-, Q- (or P/Q) - R- and T-types. To 
date 10 α1 subunit genes have been identified (Table 1 and 2 [4,5]), separated into four 
classes. The first class is the L-type channels, consisting of Cav1.1 (α1S), 1.2 (α1C), 1.3 (α1D), 
1.4 (α1F). Only the α1C (DHP-sensitive) is expressed in high levels in cardiac muscle. The 
second class contains Cav2.1 (α1A), 2.2 (α1B), 2.3 (α1E) which form P/Q-, N- and possibly R-
type channels, respectively and are all found in brain. They are primarily responsible for 
initiation of synaptic transmission at fast synapses in the nervous system. They have a 
larger intracellular loop connecting domains II and III, which contains a synaptic protein 
interaction site that binds SNARE proteins involved in exocytosis [6]. The third class of 
channels are the T-type channels, Cav3.1 (α1G), 3.2 (α1H), 3.3 (α1I) which are localized to the 
brain, kidney and heart and originally called low voltage activated (LVA) channels and unlike 
L-type channels, they are relatively insensitive to DHPs. Cav3 channels conduct T-type Ca
2+ 
currents which are important in wide variety of physiological functions, including neuronal 
firing, hormone secretion, smooth muscle contraction, cell proliferation of some cardiac 
tissue and myoblast fusion. In the heart, T-type channels are abundant in sino-atrial 
pacemaker cells and Purkinje fibers of many species and are important in pacemaker activity 
by setting the frequency of action potential firing. It has been reported that the T- type 
channels are re-expressed in the ventricle of some animal models of heart failure (HF) 
suggesting that T-channels play a role in cardiac disease. The neuronal T-type channels can 
generate low-threshold spikes that lead to burst firing and oscillations which are prominent 
in the thalamus and implicated in variety of neurological disorders [5]. In addition to these 
well characterized Ca2+ channels, the cloning of a single Cav-like protein suggest the 
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existence of a fourth subfamily [7]. This novel protein contains conserved amino acids found 
in Ca2+ (EEEE) or Na+ channels (DEKA), including EEKE residues in the corresponding region 
of its pore loops. However, this new putative channel has not been functionally expressed in 
a heterologous expression system (Xenopus leavis oocytes).  
The α1 subunit incorporates the ion-selective pore, voltage sensor, gating machinery, and 
the binding sites for channel-modulating drugs [3,8,9], and is autoregulatory. The α1-subunit 
is a substrate for protein kinase A, protein kinase C, and Ca2+-calmodulin dependent kinase. 
The pore is asymmetric, with conserved glutamate (EEEE) or aspartate residues comprising 
the ion-selectivity filter(s) [10-13], located between segments S5 and S6 of each motif. 
Cloning and analysis of the VDCC have revealed that the positively charged fourth 
transmembrane segment (S4) of each motif is highly conserved and is likely to form an α-
helix in which every third or fourth residue is basic (Arg or Lys). It is thought that the S4 
α-helices traverse the membrane electric field and that, as a response to a depolarizing 
stimulus, they move outward into the extracellular space and initiate conformational changes 
from non-conducting to conducting states of the channel (‘sliding –helix model’) (reviewed in 
ref. [14]). However, the emerging models are still controversial. Most structure-function 
studies support a spiral or rotational motion of the S4 or S3 plus S4 α-helices through the 
channel protein in order to move gating charges across the membrane electric field.  
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Tab.1Table 1. Physiological function and pharmacology of calcium channels 
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1.1.2. Accessory subunits  
 
α2/δ subunits 
The α2δ subunits are closely associated with the α1 subunit by surface interaction and 
intracellularly linked through a disulfide bridge to a small protein, the δ subunit. The α2 
subunit is entirely extracellular and δ has a single transmembrane region with a very short 
Tab.2Table 2. Nomenclature and relationships of voltage-gated calcium channels. 
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intracellular part. The α2 and δ subunits are encoded by the same gene which is separated 
by proteolytic cleavage [15]. Ellis et al. [16] first cloned the α2/δ subunit from rabbit 
skeletal muscle thinking there was only one product from the gene. Presently, at least 4 
isoforms encoded by separate genes and have been identified (α2/δ1, 2, 3, 4) [15,17,18]. The 
issue of in vivo structure-function has yet to be resolved. In heterologous expression 
systems, co-expression of the α2/δ subunit affects α1 function by increasing channel 
density, charge movement and Bmax of drug binding (e.g. the DHP, isradipine), with smaller 
effects on KD and variable minor effects on channel kinetics [19-21] (and references cited 
therein). It is probable that α2/δ and β subunits “drive" the α1 subunit to the membrane in 
the correct insertion mode. The α2/δ1 subunit is ubiquitously distributed, and possesses a 
stereo-selective high-affinity binding site for certain GABA-antagonists, such as the drug 
gabapentin, (1-aminomethyl cyclohexane acetic acid) which is widely used to treat epilepsy, 
pain, sleep disorders, and many other paroxysmal neurological conditions [22-24]. The α2/δ2 
subunit also binds gabapentin but at a low affinity, while α2/δ3 and α2/δ4 do not bind this 
drug. Mice deficient in α2/δ2 exhibit neurological dysfunction such as enhanced seizure 
susceptibility and cardiac abnormalities, viz. a tendency to bradycardia [25]. The recently 
cloned human α2/δ4 [17] is localized to fetal liver, colon, pituitary, and adrenal gland, and is 
associated with the α1C-subunit (Cav 1.2) and the β3 subunit. This reinforces the complexity 
of L-VDCCs, since subunit association appears to confer biophysical properties [10,20]. This 
rich diversity opens avenues for exciting physiological and pathological discoveries [26].  
The γ subunits 
It was originally thought that the γ subunit was the product of a single gene and only 
existed in skeletal muscle [18]. It is interesting that characterization of a genetic defect 
that induces epileptic seizures in stargazer mice [27] led to the detection of a family of at 
least 5 novel isoforms of the γ subunit that are almost exclusively expressed in brain. To 
date, 8 genes, encoding a variety of γ subunit isoforms have been identified [28]. Although 
Cavγ1 is associated specifically with skeletal muscle Cav1.1 channels, there is evidence that 
the γ2 subunit interacts with AMPA receptor subunits [29] and possibly other membrane-
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signaling proteins. Unlike other auxiliary subunits (β and α2/δ), the γ subunits do not have a 
significant role in the membrane trafficking of the calcium channels. γ1 modulates the 
biophysical properties of the Ca2+ channel. Clearly this is a very important subunit, but since 
it does not appear to be expressed in heart, it is not discussed further. 
 
β Subunit structure 
Four β subunit (β1−β4) isoforms have been described. All are hydrophilic, non-glycosylated, 
and located within the cell and only β2 has been reproducibly shown to form cardiac L-
VDCCs. The β subunit does not have a membrane spanning region. It is tightly bound to a 
highly conserved motif in the cytoplasmic linker between repeats I and II of all cloned high 
voltage-activated α1 subunit isoforms, called the α-interacting domain (AID) [30,31], and 
also to a secondary site [32]. Just recently, elucidation of the high-resolution 3D structure 
[32-34] of a β subunit has shed light on the molecular mechanism of binding of the α1 to β 
subunits. Previous work suggested that the β subunit interacts with α1 primarily through a 
highly conserved 30 amino acid motif within the β-subunit, called the β-interaction domain 
(BID), which binds directly to the AID. However, Van Petegem and colleagues [33] reported 
that the BID engages the AID through a conserved hydrophobic cleft, and named the α-
binding pocket (ABP). Interference with AID-ABP binding might provide a novel way to 
modulate Ca2+ channel function in pathological states. The I-II loop of the α1-subunit 
contains an endoplasmic reticulum retention signal that restricts cell surface expression. 
The β-subunit reverses the inhibition imposed by the retention signal [35].  
 
The roles of the β auxiliary subunits in influencing channel function 
Though much knowledge has been accumulated about the multiple roles for the β-subunit in 
the processing and functioning of L-VDCC using heterologous recombinant co-expression of 
the different subunits [20,36], the physiological significance of subunit interaction in the 
context of native tissue is only just beginning to be studied via transgenic approaches and 
adenovirus-mediated intracellular incorporation of genes, encoding Ca2+ channel β-subunits 
into single cells [3,37,38]. In general, co-expression of the β-subunits modulates the 
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biophysical properties of the L-VDCC α1 subunit, producing a substantial increase in Ca2+ 
current amplitude and/or changes in the current kinetics (leftward shift of the current-
voltage (I-V) relationship) which is consistent with the involvement of the S4 region of 
the α1 subunit voltage sensor region. Moreover, it has been shown that α1 subunits 
expressed in the absence of β subunits are not regulated by the β-adrenergic system [39] 
or by pH changes [40]. Frequency- and prepulse-dependent facilitation of L-VDCC activity is 
regulated by certain classes of β subunits [41]. By employing an antisense strategy to lower 
the numbers of endogenous β subunits in oocytes, leaving only α1 subunits intact, a loss of 
current occurred, implying that the β subunit functions in the assembly and expression of 
the α1 subunit [42]. Dr. Schwartz’s group provided evidence that the β subunits have a 
chaperone-like role, in trafficking α1C subunits from the ER to the plasma membrane, and 
inserting in its proper geometry [43]. Viard et al. [44] demonstrated that a region of this 
β2a subunit is involved in phosphatidylinositol 3 kinases (PI3K)-induced increases of Cav1.2 
(rat brain) channel density. The PIK3-induced regulation is mediated by PIP3–activated 
Akt/PKB and requires phosphorylation of Cavβ2 subunits on Ser574, which is common to all 
splice variants of the β2 subunits. These results indicate that PIK3 regulates Ca2+ channel 
trafficking to the plasma membrane and may be a general mechanism for the regulation of 
Ca2+ entry into excitable cells [44]. The β1-subunit also has a crucial role in EC coupling as 
proven by β1-KO mice with impaired EC coupling and early lethality [45]. The exact 
mechanism for the lack of EC coupling is not known but it is possible that the deficiency in 
the assembly process of the α1/β complex results in the degradation of the α1 subunit. The 
role of the β2 subunit in EC coupling is unclear [46]. β3 null mice have no detectable 
abnormalities in the heart [47]. 
Hullin et al. [48] cloned two distinct β subunits, β2 and β3, from rabbit heart and showed an 
association with the α1 subunit of the L-VDCC. The amino acid homology of these subunits 
was similar to that of β1, originally cloned from skeletal muscle [9]. It should be noted that 
β2a, an important subtype of this subunit, is palmitoylated [49,50]. This modification is 
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associated with membrane targeting of non-transmembrane proteins (such as the β subunit) 
to specific areas including the plasma membrane. The role of the β subunits in L-VDCC 
expression is well characterized although we still do not know how the β subunits modulate 
preexisting α1 subunit expression. Colecraft et al. [51] devised a novel system in which 
recombinant adenoviruses were used to express GFP-fused β1–4 subunits in cultured adult 
rat cardiomyocytes. While all four subunits (β1b, β2a, β3, β4) increased ICa density, their 
effects on inactivation kinetics were non-uniform. The conclusion of this study was that 
overexpression of the newly cloned rat splice variant of a β2b in adult rat heart cells yielded 
channels that were identical to that in the native unmodified rat heart cells.  
β3 is most abundant in brain but also is expressed in heart, aorta, lung, trachea, and skeletal 
muscle. Expression levels of various β subunit isoforms [48,51,52] indicate that altered 
single-channel behavior in human heart may be due to differential effects and changes in β 
subunit gene products. 
 
1.1.3. Regulation of intracellular Ca2+: Cardiac Dysfunction 
The control of myocardial Ca2+ is crucial for the maintenance of normal rhythm, regulation 
of contraction, enzymatic reactions, as well as, growth and development. For many years, 
drugs modifying cardiac function by affecting myocardial Ca2+ have been used to modulate 
Ca2+ fluxes, levels of Ca2+ at storage sites, or increase the Ca2+ sensitivity of the contractile 
proteins. In general, drugs that reduce Ca2+ loading of the cardiac myocyte serve to 
“protect” the heart from the ultimate cause of myocardial cell death, i.e., Ca2+ overload. 
Among the many problems that arise from Ca2+ overload, ventricular tachycardia is the most 
prominent and is often life threatening. Both early and delayed after-depolarizations can be 
treated with Ca2+ channel-blockers (CCBs). Likewise, arrhythmias ascribable to disorders of 
conduction are also treated with CCBs that function presumably by inhibiting conduction 
disturbances in the sinoatrial or atrioventricular junction. Clinical trials show that CCB’s do 
not reduce mortality of heart failure. The state of art in pharmacotherapy of heart failure, 
considering its epidemic nature in the world, is very disappointing. Recent reviews have 
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emphasized that we are dealing with a highly complex, multifaceted disease almost similar 
to the cancers [53-57].  
Although considerable information is known regarding the L-VDCC and its role in EC 
coupling, the consequence of increased Ca2+ channel density remains speculative and 
controversial. In Dr. Schwartz’s laboratory a transgenic mouse model was designed 
overexpressing the L-VDCC α1C subunit (α1C-Tg) as a way to increase [Ca2+]i. The transgenic 
mouse model exhibits a sustained, low level [Ca2+]i increase in cardiac cells throughout the 
life of the animal; hypertrophy develops slowly and the ensuing failure occurs at 9-12 
months. This model mimics human dilated, hypertrophic-(ischemic) cardiomyopathy. 
 
1.1.4. Ca2+ channel antagonists (blockers, “CCB”) and Ca2+ binding 
domains 
L-VDCC is an important pharmacologic target in the treatment of a number of conditions. In 
the late 1960s, Fleckenstein showed that Ca2+-antagonists like verapamil protected the rat 
heart against structural damage associated with prolonged [Ca2+]i overload. Among the many 
problems that arise from Ca2+ overload, ventricular ectopic rhythm is the most prominent 
(ventricular fibrillation). In pharmacological models, the CCBs are considered promising 
drugs to treat supraventricular arrhythmias, hopefully preventing lethal ventricular 
fibrillation (VF).  
Using a variety of techniques, several laboratories have identified individual amino acids 
within the L-VDCC α1 subunit that participate in the formation of the major drug-binding 
domains. Three classes of organic CCBs, include: Dihydropyridines (DHPs), phenylalkylamines 
(PAAs), and benzothiazepines (BTZs). Each drug type, DHP, PAA and BTZ has separate but 
overlapping, or allosterically-linked, Ca2+ channel-binding sites at IIIS6 and IVS6, IVS6 and 
IIIS6, and IVS6 motifs (Figure 2), respectively. Nine amino acid residues in segments 
IIIS5 [58], IIIS6 [59] and IVS6 contribute to the “DHP pocket”. The four amino acid 
region (YMAI) in motif IVS6 is a common binding site for both BTZ [60] and PAA [61,62].  
DHPs block the calcium channel at the extracellular level and have greater vascular 
selectivity than other classes of CCBs. When used clinically, as a result of vigorous 
peripherial vasodilatation, they tend to cause reflex tachycardia and often increase 
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contractility, as catecholamines activate the calcium channel intracellularly, on a different 
site from that blocked by DHPs. Tissue selectivity is considered to be one of the most 
beneficial properties of CCBs as it diminishes the likelihood of undesirable side-effects. In 
general, vascular selectivity permits coronary and peripherial dilatation in the absence of 
significant myocardial depression. Nifedipine is at least 10 times more vascular than 
myocardial-selective compared to Verapamil and Diltiazem. Nisoldipine and felodipine are at 
least 1000 times more selective than nifedipine. On the other hand it can be a disadvantage, 
causing adaptive reactions. Verapamil and Diltiazem have prominent effects on nodal tissues. 
The BTZs are thought to approach their binding site on Cav1.2 from the extracellular face 
of the plasma membrane [63]. Verapamil and Diltiazem have a use-dependent or a 
frequency-dependent effect. The more frequently the calcium channel opens, the better 
the penetration to the binding site. This explains their effect on nodal tissue in paroxysmal 
supraventricular tachycardia. The general absence of ‘use-dependence’ and the presence of 
voltage-sensitivity of DHP binding explain their vascular selectivity. The use-dependent 
blockade by diltiazem of L-VDCCs would be expected to inhibit large increases in Ca2+ influx 
accompanying a sudden increase in heart rate. In addition, the acceleration of inactivation 
would be expected to reduce Ca2+ influx during action potentials that arise from normal 
negative resting potentials. Both of these effects likely contribute to the beneficial effect 
of Diltiazem when used as a prophylactic or depressant of supraventricular tachycardia 
[64,65]. Diltiazem facilitates the inactivation of the channel both by accelerating the 
transition from the activated state to the inactivated state and by decelerating the 
transition from the inactivated state to the available state. However, these drugs have not 
emerged unequivocally favorable in all clinical studies to date. Verapamil and Diltiazem can, 
in some cases, prevent episodes of acute ischemic VF in humans, but they do not have much 
of a beneficial effect on overall mortality as do the β-blockers, and the ACE inhibitors. The 
clinical implications of this finding reported in different clinical trials are similar to that 
reported for encaidine and flecainidine in the Cardiac Arrhythmia Suppression Trial [66]. 
Patients suffering from coronary disease may die of either heart failure or arrhythmias. 
Likewise, arrhythmias ascribable to disorders of conduction are also treated with CCBs that 
function, presumably, by inhibiting conduction disturbances in the sinoatrial or 
atrioventricular junction. Although CCBs bind specifically to regions of the α1C subunit of 
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the L-VDCC, these drugs are not currently judged as being helpful in the setting of 
congestive heart failure. In fact, all clinical trials to date, with the exception of the 
Prospective Randomized Amlodipine Survival Evaluation (PRAISE I) study in where the 
patents had congestive heart failure, were a failure. However, a sub-group analysis (PRAISE 
II) revealed that improved clinical symptoms were seen only in patients with heart failure 
of a non-ischemic cardiomyopathic nature. A favorable effect on survival was found only in 
patients without a history of angina [67]. In the Third Vasodilator-Heart Failure Trial [68] 
(V-HeFT III), felodipine was administered to patients with congestive heart failure in a 
setting of stable therapy with enalapril, diuretics and digoxin. The drug had neither a 
beneficial or deteriorating effect despite the improvement in exercise performance and LV 
function, as reported previously in the V-HeFT II trial in patients with chronic CHF [69]. 
Chronic Nifedipine (has a strong peripheral vasodilating effects) therapy caused a higher 
incidence of clinical deterioration and worsening of HF [70,71]. The DEFIANT-I study 
(Doppler Flow and Echocardiography in Functional Cardiac Insufficiency: Assessment of 
Nisoldipine Therapy) was a double-blind randomized study of the effects of the DHP 
nisoldipine on left ventricular (LV) size and function after acute myocardial infarction (MI). 
Diastolic LV function improved in patients recovering from acute MI [72]. The Danish 
Verapamil Infarction Trial II (DAVIT II) demonstrated that long term treatment with 
verapamil significantly improved reinfarction survival after acute MI. Verapamil 
significantly reduced (35%) the 18 month mortality rate, but produced no change in 
mortality in the heart failure (HF) group [73]. Hypertensive patients are often treated with 
CCBs to reduce cardiovascular disease risk, but the overall benefit compared with atenolol 
and hydrochlorothiazide and ACE inhibitors is controversial and problematic. The Controlled 
Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial indicated 
that the effectiveness of CCB therapy was comparable to diuretic and β-blocker treatment 
in reducing cardiovascular disease [74]. According to the Multicenter Diltiazem 
Postinfarction Trial [75] analysis diltiazem exerted no overall effect on mortality or cardiac 
events in a large population of patients with previous infarction, but in patients with 
pulmonary congestion diltiazem was associated with an increased number of cardiac events 
and mortality. Interestingly, the increase in mortality was not accompanied by a worsening 
of HF. Despite these concerns, in the Studies of Left Ventricular Dysfunction Trial 
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(SOLVD), 3-35% of the patients were treated with CCBs in addition to digitalis and 
diuretics. CCB use was associated with significantly increased risks of fatal and nonfatal MI 
[76]. CCBs have a favorable systemic vasodilator effect and should improve diastolic 
relaxation. One would assume that CCBs inhibiting Ca2+ influx into myocardial cells might be 
beneficial because theoretically they could reduce Ca2+ overload, an important trigger for 
activating certain downstream Ca2+-dependent pathways involved in hypertrophy and cardiac 
dysfunction. Clinical trials to date however have been disappointing. In fact, it has been 
suggested that the effects of CCBs on mortality in patients with HF may be associated with 
increased sympathetic activity. Summing up the therapy of heart failure, the β-AR 
blockers, ACE Inhibitors (angiotensin-converting enzyme inhibitors)), diuretics, and 
aldosterone receptor(s) inhibitors (spironolactone and new derivatives) have achieved 
therapeutic success probably through multiple actions that culminate in a positive 
"remodeling" of the diseased heart ([77] Review). The state of art in the pharmacotherapy 
of heart failure, considering its epidemic nature in the world, is also disappointing.  
As discussed above, although CCBs bind specifically to regions of the α1C subunit of the L-
VDCC, these drugs are not currently judged as being helpful in the setting of congestive 
heart failure, and should be if used at all, with caution. All clinical trials underscore the use 
of drugs that inhibit the sympathetic nervous system and reduce the load on the heart.  
Use-dependence 
Less detailed structural information is known regarding the mechanism of use-dependent 
block, a feature that is critical to the activity of therapeutically successful L-VDCC 
antagonists. The modulated receptor theory states that drug affinity for a specific 
receptor on the channel is modulated by the channel state. The model has been proposed 
(modulated receptor hypothesis) that can account for the voltage and use-dependent block 
of Na+ channels by local anesthetics [78,79]. Each channel (sodium and calcium) blocker has 
a characteristic association and dissociation rate constant for channels in each of these 
states. The more frequently the Ca2+ channel opens, the better penetration is for the drug 
to reach the binding site. Verapamil and Diltiazem preferentially interact with the open and 
inactivated states of the channel (reviewed in ref.[80], explaining their preferential effect 
on nodal tissue. Single amino acids have now been identified as inactivation determinants in 
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motifs IIIS6, IVS6 and IVS5 with some of them also serving as high affinity determinants 
for the DHP receptor site [80-82]. 
Diltiazem is the prototype benzothiazepine and is the only drug of this type currently in 
clinical use (Cardizem). Diltiazem exhibits modest selectivity for block of vascular muscle 
over cardiac muscle L-type channels, but is also useful in treatment of arrhythmias due to 
the block of L-type channels in the heart. The BTZ binding site on L-VDCCs is allosterically 
linked to the binding sites for PAAs and DHPs. BTZ binding inhibits PAA binding but 
stimulates DHP binding to L-type channels in a temperature dependent manner. Diltiazem 
was found to produce more tonic block than methoxyverapamil but less than nifedipine and 
nitrendipine. The frequency-dependent block by Diltiazem is due to rapid binding to the 
open state and preferential binding to the inactivated channel. 
 
1.1.5. Voltage-gated cation channels  
The gating of most ion channels is regulated by different specific mechanisms, which change 
their permeation properties: membrane potential (voltage-gated ion channels), specific 
chemical signals such as Ca2+ or synaptic transmitters (ligand gated ion channels), or changes 
in the membrane conformation (mechanosensitive or volume sensitive ion channels etc.). 
Voltage-gated cation channels are responsible for the generation and propagation of action 
potentials. Whereas potassium channels form tetramers of four identical domains, the main 
molecule of the Na+ and Ca2+ channels is one large subunit. The pore of the voltage-gated 
cation channels is formed by the loops, which are located in between the S5 and S6 
transmembrane regions of the four domains/motifs. The S4 segments contain four to eight 
positively charged residues conferring voltage dependence to the channel protein (for a 
review see [3,83]. At the resting membrane potential (-60 to –90mV) the channels usually 
reside in closed state and are not permeable for ions (Figure 2 [83]). At very hyperpolarized 
potentials, where the channels are in their resting state, inactivation is removed (steady-
state inactivation curve). This means that the inactivation gate is not occluding the channel 
and if nothing else was in the way ions could flow through the pore. However at those very 
negative potentials, the activation gates are all closed. Those closed gates block the pore 
and prevent conduction. Upon depolarization, they open their gate and can conduct ions, a 
process called activation. This is triggered by the movement of the voltage sensors. Some 
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of the channels, after the opening of the activation gate, can close another existing gate 
upon ongoing depolarization a process called inactivation. The inactivation gates begin to 
close, but with a slower time course than the activation gates. The inactivated channels 
require time at hyperpolarized potentials before they can be activated again (recovery from 
inactivation). During this refractory period the channels recover from the inactivated state. 
Voltage gated ion channels can have more inactivated states which are kinetically distinct. 
Upon hyperpolarization, the opened activation gate closes in a process called deactivation. 
In general, voltage-gated ion channels are characterized by at least one open (O) and one 
closed (C) state and may have one or more inactivated (I) states (Figure 2A [83]). 
 
 
 
Figure 2. Gating transitions in voltage-gated cation channels. (A) Schematic representation of the main 
conformational states of voltage-gated channels and the transitions between them. (B) Mechanistic view of channel 
gating [83]. 
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2. MOLECULAR BIOLOGICAL METHODS 
2.1. cDNA constructs and mRNA 
Restriction enzymes were used to linearize plasmid cDNA for in vitro cRNA synthesis. All 
restriction enzymes were used according to the manuals of the suppliers. The cDNA for the 
human heart α1C (HHT-α1C, Accession number L04569) [84] subunit used in this project was 
subcloned into the ΗindIII/NotI sites of the pBS SK- (Stratagene) vector. Rabbit lung 
α1Cb (VSM-α1Cb Accession number X55763) [85] was subcloned into the pSP72 vector 
(Promega). The cDNAs must be linearized prior to generating mRNA. This allows the RNA 
polymerase to transcribe the cDNA only once, at the end of the cDNA the RNA polymerase 
“falls off” the DNA. 
 
Figure 3. The map of pBS SK-vector and the pSP72-vector with the insertion of recombinant HHT-α1C and 
Lung-α1Cb, respectively. The vectors are showing the positions of the ampicillin resistance gene or the β−lactamase 
coding region and selection of the most important restriction sites. 
 
 
All restriction enzymes that were used to linearize the plasmid cDNAs for in vitro mRNA 
synthesis were used according to the protocols of the supplier. 
For these experiments, 30-50µg of DNA was digested overnight (to a final volume of 
400µl) with specific restriction enzymes. HHT-α1C was linearized with XbaI (NEB), VSM-
α1Cb linearized with Acc651 (a neoschizomer of KpnI, NEB), rabbit skeletal muscle α2/δ−1 
XbaI, 40
ClaI, 520
DraI, 879
DraIII, 1531
StuI, 2171
EcoRI, 2553
BspHI, 3896EcoRV, 4687
4918, DraI
5035, DraIII
4980, BstPI
5306, ScaI
5393, FspI
6955, Acc651
7032, HpaI
8224, BglI
8326, FspI
8474, PvuI
8584, ScaI XmnI, 8703
SspI, 8908
AatII, 9026
NdeI, 9275
Rabbit Lung α1C
(Cav1.2b)
β-lactamase coding region
6949, SmaI
6961, SacI
6963, EcoRI
6970, ClaI
6977, EcoRV
6981, BglII
AccI, 35
SalI, 34
PstI, 32
SphI, 26
HindIII, 16
PvuII, 12
XhoI, 4
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[16](SK-α2, Accession number M21948) was linearized with NheI (NEB) and human heart 
β3-subunit (Accession number L06112) [86] was linearized with NotI (NEB). These enzymes 
were chosen because they have unique restriction sites (cut only once) and generate 5’ 
overhangs (Figure 4).  
5’-CCCGGGGGTACCGAGCTC-
-GGGCCCCCATGGCTCGAG-3’
SmaI Acc651 SacI
5’-ACTAGTTCTAGAGCGGCCGC-
-TGATCAAGATCTCGCCGGCG-3’
SpeI XbaI NotI
Human Heart α1C
Rabbit Lung α1C
 
 
Figure 4. Enzyme restrictions of the Lung-α1Cb and HHT-α1C DNA molecules, respectively. Figure illustrates the 
detailed positions of the recognition sequences for Acc651 and Xba1, respectively. Before transcription of cDNA 
to mRNA the circular DNA has to be linerized using restriction enzymes. These endonucleases break the internal 
phosphodiesterase bonds at a very specific position which is characteristic for every enzyme. 
 
 
After overnight digestion, the samples were phenol/chloroform extracted and then 
precipitated with Ammonium Acetate and Ethanol to remove impurities. The DNA pellet was 
resuspended in 30µl RNase-free water and the concentration was determined by the 
Optical Density at wavelengths 260 and 280 (OD260/280),  
 
2.1.2. In vitro RNA synthesis 
All reagents and materials were kept on ice. The commercial kit mMessageTM mMachine 
(Ambion) was used to generate mRNA using the T7 promoter for HHT-α1C, α2-1 [72] and 
hβ3 and the SP6 promoter kit was used for RL-α1Cb following the manufacturer’s protocol. 
1µl GTP was added to the reaction mixture to compensate for the long message. In brief, 
the linearized plasmid DNA was incubated for 2 hours with the transcription buffer, the 
ribonucleotide mix and the enzyme mix at 37°C. Additionally 1µl RNAse-free DNAse type I 
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(2U/µl) was added and the mixture was incubated for 15 more minutes at 37°C to remove 
DNA. After mRNA synthesis, the mRNA was precipitated with Lithium Chloride (as stated 
in the manufacturer’s protocol) followed by a resuspension in 100µl RNase-free water. The 
mRNA was then precipitated with Ammonium Acetate and Ethanol to further remove any 
unincorporated nucleotides. The removal of unincorporated nucleotides is essential because 
their presence will artificially increase the mRNA concentration as determined by 
OD260/280. After precipitation with ammonium acetate, the mRNA is resuspended in 
RNase-free water. The amount of water used depended on the size of the mRNA pellet, 
usually between 50-80µl. The concentration of mRNA was determined by OD260/280.  
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3. MATERIALS AND METHODS 
 
3.2. Spectroscopic measurement of nucleic acid concentration 
To determine the concentration of the DNA and RNA probes the absorption at 260nm 
(A260) optical wavelength was measured on an automated spectrophotometer (UV-Visible 
Spectrophotometer, UV-1650 PC, SHIMADZU). Appropriate nucleic acid dilutions were 
prepared to obtain absorption between 0 and 1. An Optical Density (OD) of 1 corresponds to 
a concentration of 50µg/ml for DNA and 40µg/ml for RNA. A qualitative test was done by 
measuring the ratio A260/A280 (Absorption at 260 and 280nm wavelengths). A ratio 
between 1.6 and 2 was considered to indicate purified DNA or RNA.  
 
3.1. Agarose gel electrophoresis 
The quality of the mRNA is determined by running formaldehyde based RNA gel 
electrophoresis on the samples. The mRNA is place into a solution containing formaldehyde, 
formamide and MOPS. This is run on a 1% agarose gel also containing formaldehyde, 
formamide and MOPS. Staining the gel with ethidium bromide after electrophoresis 
(followed by destaining with water) allows the mRNA to become visible under UV light. Any 
unincorporated nucleotides show as a blurry band at a lower molecular weight.  
 
3.3. Oocyte preparation and injection 
The use of Xenopus laevis oocytes as an expression system for ion channels was first 
described by Miledi et al. [87] in 1983 and since then has become a standard technique for 
investigation of ion channels. Oocytes are especially suitable for electrophysiological 
recordings, since they have only a few endogenous channels, and faithfully express foreign 
RNA that has been injected.  
 
3.3.1 Frog surgery 
All the experiments were carried out in accordance with the University of Cincinnati 
Institutional Animal Care and Use Committee. Adult female Xenopus laevis (XenopusI, Ann 
Arbor, MI) frogs with a length of at least 9cm were anesthetized in 1L 0.5% Tricaine water 
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solution (3-aminobenzoic acid ethyl ester methanesulfonate salt (MS-222), Sigma-Aldrich, 
USA) for about 15-20min. The frog was put on its back on ice after achieving the necessary 
anesthetic grade checked by the loss of the righting response and the loss of response to 
painful stimuli. Extremities and head were covered with ice in order to prolong the effect 
of the anesthetic and to prevent excessive bleeding. The surgical area and all surgical 
instruments were sterilized with 70% ethanol solution. Instruments were kept on a sterile 
wrap during the procedure. Skin, muscle fascia and muscle tissue were cut at a length of 
1cm. A portion of the ovary was removed through this opening with forceps and scissors and 
placed in OR-2 medium.  
 
3.3.2. Defolliculation and selection 
Before defolliculation, oocytes were extensively washed with OR-2 medium (in mM: 82.5 
NaCl, 2 KCl, 1 MgCl2, 5 HEPES, pH 7.5). Defolliculation was achieved by treatment with 
2mg/ml collagenase (type IA; Sigma-Aldrich, USA) dissolved in OR-2 Ca2+ free medium. 
Usually 2 hours of gently shaking at room temperature were enough to defolliculate the 
oocytes completely without damaging the vitelline membrane. Defolliculated stage V-VI 
oocytes were incubated in P/S medium (in mM): 96 NaCl, 2.0 KCl, 1.0 MgCl2, 1.8 CaCl2, 5.0 
HEPES, 2.5 sodium pyruvate, and 0.5 theophylline at pH 7.5. The P/S medium was 
supplemented with 100µg/ml streptomycin and 100 units/ml penicillin at 19°C in low 
temperature aseptic incubator (VWR Scientific, West Chester, USA). Medium was changed 
every day. Before injection, a selection was done for healthy stage V and VI oocytes [88]. 
 
3.3.4. Oocyte microinjection 
In vitro synthesized mRNA can be injected and expressed in Xenopus laevis oocytes. 
Borosilicate glass pipettes (210/310/510, Drummond Scientific, Broomall, PA USA) were 
pulled on a vertical pipette puller, Model 720 (David Kopf Instruments, Tujunga, California). 
The tips of the pipettes were broke under a StereoZoom 3 microscope (Nikon,, Japan) to 
obtain optimal diameter and sharpness (around 20µm tip diameter). Pipettes were filled 
with heavy mineral oil (Sigma-Aldrich, USA) and were mounted in the head-stage of a 
Drummond Digital Microdispenser, Cat. #3-000-510 (Drummond Scientific Co., Broomall, PA 
USA). The pipette tip was filled with 2µl RNA.  
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Figure 5. The Xenopus oocyte expression system. (A) Adult female Xenopus leavis frog (B) Developmental 
states of Xenopus leavis oocyte: healthy stage V and VI oocyte can be recognized by their size and by their clear 
differentiation of the animal (dark) and vegetal poles (light).  
 
 
Oocytes were lined up on a plastic grid previously sterilized with 70% ethanol and covered 
with culture medium. 50nl undiluted mRNA were injected in the vegetal pole of a single 
oocyte. After injection oocytes were stored in groups of 20 per plates and incubated at 
19°C. The amount of the injected RNA correlated well with expression levels, i.e. current 
size was dependent on the expression rate. With a concentration of 1µg/µl mRNA, the 
amount of mRNA injected to each oocyte is about 50ng. In order to compare current 
amplitudes of Cav1.2 L-VDCC channels HHT-α1C [84] and rabbit lung VSM-α1Cb (a generous 
gift from Dr. R. Hullin) [85], RNA preparations were injected on the same day into the same 
batch of oocytes and measured in parallel on days 2-4 after injection. In order to increase 
current density and stabilize gating, the calcium channel α1C-subunit encoding mRNA was 
co-injected with mRNA encoding the β3 [86] and α2/δ−1 [16] calcium channel subunits in a 
1:1:1 molar ratio (the final concentration remains 1µg/µl or 1ng/nl). To minimize 
A 
B 
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contamination with chloride current, oocytes were microinjected with 50nl of a 40mM K4-
BAPTA solution (potassium 1,2-bis(2-amino-phenoxy)ethane-N,N,N’,N’-tetraacetate in 10mM 
HEPES, pH 7.05) 60min prior to current recording. 
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4. ELECTROPHYSIOLOGY 
 
4.1. Reagents and solutions 
Solutions for voltage-clamp measurements 
All reagents were ordered from Sigma-Aldrich (St. Louis, MO USA). 
  
4.2. General procedures 
Most of the current knowledge about ion channels in cell membranes derived from 
experiments using voltage clamp. In the voltage clamp technique, the membrane potential is 
held constant with a feedback amplifier while the current flowing through the membrane is 
measured. Current is measured because the investigator has no direct way of measuring 
conductance. The method was developed by Cole [89] in 1949 and Hodgkin and Huxley [90]. 
Since that time many variants of the technique have evolved and voltage clamp 
measurements have been extended to a wide range of tissues.  
 
Figure 6. (A) Simplified electrical circuit of membrane that contains only voltage-gated Na+ channels. Cm, 
membrane conductance; gNa, Na+ conductance. (B) The current elicited by a voltage clamp depolarization consist of 
a brief initial capacity current followed by an ionic current. In this case, the ionic current only flows through 
voltage-gate channels. The Na+ current flows from the outside to the inside of the membrane. Edited by Ashcroft 
FM, Ion Channels and Disease (Book), Academic Press, 2000, UK. 
 
The current that flows through the membrane at any particular potential can be measured 
(It). This current is the sum of the ionic current (Ii), which represents current flow through 
open ion channels and the capacitive current (Ic), which is largely due to charging of the 
membrane capacitance. The magnitude of the capacity current is determined by the 
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capacitance of the cell membrane (Cm), which is normally 1µF/cm2, and it flows only while the 
voltage is changing (Figure 6).  
Thus, It=Ii+Cm x dV/dt. Since IC =C dV/dt, once the potential is clamped, no capacitive 
current flows. Hence, IC flows only during the membrane-clamping process. Clearly, the ionic 
current will be the same as the total membrane current. The good voltage clamp requires 
that the membrane potential be changed rapidly, so that the capacity current is over before 
the ionic current starts to flow. The speed of the voltage response is limited by the rate at 
which current can be injected to the microelectrode. This depends on the electrode 
resistance.   
 
4.2.1. Basic apparatus with electrical and mechanical isolation 
A patch-clamp set-up may consist of a chamber, a microscope (for cell visualization) placed 
on an anti-vibration table (pneumatic support for the patch clamp setup and passive support 
for the two electrode voltage clamp measurements), a patch clamp amplifier and pulse 
generator for voltage-clamping the cells, a micromanipulator holding the amplifier probe for 
positioning the attached patch pipette, and data-recording devices (oscilloscope, computer). 
A Faraday cage was build around the experimental setup and all metal parts near the head-
stage were grounded, using the virtual ground input of the amplifier. An example of patch-
clamp set-up is shown in Figure 7. 
Figure 7. A common electrophysiology setup. To reduce vibration, the microscope with the recording chamber, 
manipulator and headstage should be mounted on a massive antivibration table (A and B). The glass microelectrode 
(C) is connected to a feedback amplifier (D). The amplified and filtered signal is digitized by the AD converter (E). 
The digitized signal is visualized and stored on a PC (F). Single-Channel Recording Second Edition (Book), Edited by 
Sakmann B. and Neher E., Plenum Press, 1995, USA 
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4.2.2. Glass electrodes 
Glass microelectrodes were pulled with David Kopf vertical Pipette Puller Model 720 (David 
Kopf Instruments, Tujunga, California USA) from thin wall borosilicate glass pipettes with 
filament (1.2mm OD, 0.90mm ID; A-M Systems, INC. Everett, WA, USA). The 
microelectrodes for patch-clamp recordings were pulled with Sutter and fire polished 
(Garner Glass Company, Claremont, CA USA ID 1.10, OD 1.60, Glass type 7052). The 
resistance of the whole-cell patch clamp electrodes ranged between 2 and 4MΩ. Sharp 
glass electrodes for two-electrode voltage clamp (TEVC) were pulled in a way to minimize 
the access resistance while minimizing cell damage – 0.5 to 1.5MΩ with the standard 3M KCl 
electrode solution. 
Ag/AgCl electrodes 
Ag/AgCl pellet holder’s electrodes were purchased from Warner Instruments (Catalog# 64-
1301). The bathing solution was connected to the ground through a 3M KCl/agar bridge (2% 
agarose in filtered 3M KCl). 
 
4.2.3. Digitizing, recording and analysis 
In the cardiomyocytes, the Axopatch-200A patch-clamp amplifier was used to record 
membrane currents. The voltage clamp amplifier output was digitized by a DIGIDATA 1200 
AD/DA converter (Axon Instruments, Union City, USA), connected to a personal computer 
(PC 486) running Clampex 5.6 (Axon Instruments, Union City, USA) acquisition software 
under Microsoft DOS 6.2 (Microsoft Corp. Redmond, USA). In the two electrode voltage-
clamp experiments in oocytes, we used Axoclamp-2A amplifier with pCLAMP software 
(version 5.5, Axon Instruments, USA) to generate voltage clamp protocols, acquire data and 
analyze current traces. Whole cell leakage currents were subtracted on-line using the P/4 
procedure. Current were digitized at 1kHz after being filtered 1kHz. The data were stored 
on the computer hard drive for later analysis and a hard copy record was done for every 
protocol. Analysis was done on a PC using combination of Clampfit 6.03 (Axon), Origin 
(Version 7.0 Microcal, Northampton, USA) and Excel (Microsoft XP 2003) software. 
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4.3. Patch clamp 
Instead of using sharp microelectrodes to puncture the membrane and penetrate the cell in 
traditional voltage clamping, patch-clamping uses a fire-polished pipette of about 1µm that 
is sealed to a ‘patch’ of membrane. After forming the cell-attached seal the membrane 
patch is destroyed by strong suction, electrically or it may be permeabilized with pore-
forming antibiotic nystatin. This provides electrical continuity with the cell interior allowing 
currents through the whole of the cell membrane to be measured under of the whole-cell 
current. The tightness of the gigaseal prevents the leak currents flowing between the 
pipette and the reference electrode. However, the current through the series resistance of 
the pipette and the residual resistance of the ruptured patch is often sufficiently large to 
introduce significant voltage errors. It has an advantage that the intracellular solution can 
be manipulated however, but it has a disadvantage since the cytosolic constituents are lost 
from the cell by dialysis. A typical patch clamp circuit shown in Figure 8. The key difference 
between the two electrode voltage clamp is that the patch clamp uses a single electrode 
both to control the membrane potential and to measure the current.   
 
Figure 8. One electrode continuous voltage clamp method (whole cell patch clamp circuit). A typical patch-clamp 
circuit is shown in Figure. One advantage of this system is that the patch-clamp uses a single electrode both to 
control the membrane potential and to measure current. The sensitive current-to-voltage converter is fabricated 
using a high megaohm resistor (Rf) and an operational amplifier (Feedback amplifier, A1). The patch pipette is 
connected to the inverting input of a feedback amplifier and the command voltage is connected to the positive 
input. Since the A1 has extremely high gain, the potential at the negative input is forced to follow the command 
potential (Vcmd) at the positive input. All current flowing in the micropipette also flows through Rf. This current is 
proportional to the voltage across Rf, which is measured at the output of the differential amplifier (A2). Edited by 
Ashcroft FM, Ion Channels and Disease (Book), Academic Press, 2000, UK) 
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4.3.1. Two-electrode voltage-clamp on Xenopus laevis oocytes 
Experimental setup 
Figure 9 shows a schematic diagram for the two electrode voltage clamp (TEVC) circuit. The 
oocyte is penetrated with two microelectrodes filled with electrolyte solution (typically 3M 
KCl), connected to the recording system through Ag-AgCl electrodes. In the two-electrode 
voltage clamp recording from oocytes, one intracellular electrode measures the membrane 
potential (voltage electrode-ME1) and the second passes sufficient current (current 
electrode-ME2) to maintain the desired voltage clamp, using a feedback circuit. The amount 
of current passed through the current electrode is determined by the discrepancy between 
the membrane potential and the command potential. When these two are equal, no current 
flows through the current electrode. A good voltage clamp requires that the membrane 
potential be changed rapidly so that the capacity current is over before the ionic current 
starts to flow. The main disadvantage of the TEVC is the relative slow response due to the 
high value of the capacitance of the oocyte membrane. The response time (τ) of a voltage 
clamp to a step voltage change is: τ=RICm/A where RI is the resistance of the current-
passing electrode, Cm is the membrane capacitance, and A is the gain of the command 
amplifier. Since not that much can be done about Cm, the only two things one can do in order 
to achieve fast clamping of the cell is to use the lowest RI and the largest A possible. The 
higher the electrode resistance, the more difficult it is to inject sufficient current fast. 
When studying voltage gated channels, one wants the fastest clamp attainable. A well-tuned, 
TEVC can clamp an oocytes fast enough to study the gating kinetics of most voltage-gated 
channels except Na+. A faster clamp can be achieved by recording from smaller oocytes. 
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Figure 9. Conventional Two-Electrode Voltage Clamp. (A) The membrane potential (Vm) is recorded by a unity-
gain buffer amplifier (A1) connected to the voltage recording microelectrode (ME1). Vm is compared to the 
command potential (Vcmd) in a high-gain differential amplifier (A2; gain=µ). The output of A2 is proportional to the 
difference (ε) between Vm and Vcmd. The voltage at the output of A2 forces current to flow through the current-
passing microelectrode (ME2) into the cell. The polarity of the gain in A2 is such that the current in ME2 reduces 
ε. (B) unlike the ideal case, there is a finite time is required to charge the cell capacitance. If µ (the gain of the 
clamp amplifier) was infinite, or if Rp2 (the resistance of the output ME2) was zero, the response would approach 
the ideal case. The Axon Guide for Electrophysiology & Biophysics Laboratory Techniques (1993, USA) 
In the oocyte set-up, the Plexiglas recording chamber was placed under a stereo microscope 
(StereoZoom 3, Nikon, Japan). Head-stages (HS-2, Gain: x10MG, Axon Instruments, USA) 
and pipette holders (MEH3S12 Microelectrode Holder Half-Cells-World Precision 
Instruments, Inc. Sarasota, FL USA) were fixed on Narishige manipulators. Axoclamp-2A 
amplifier was used for all TEVC measurements. 
 
Experimental procedures 
The voltage electrode was wrapped in aluminum foil in order to reduce the capacity coupling 
between current and voltage electrodes. In order to minimize the capacity Cm (Figure 9), the 
recording chamber was filled with solution just enough to cover the oocyte. The cell was 
fixed on a grid in the recording chamber. The tips of the two electrodes were inserted in 
the bath solution. Electrode potentials were compensated, while the amplifier was switched 
to current clamp mode. The voltage electrode was inserted in the oocyte and the resting 
membrane potential was measured. Cells with a resting membrane potential more negative 
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than –20mV were only measured. In whole cell patch clamp experiments Series resistance 
and capacity compensation were performed, using the circuits present in the amplifier.   
Advantages of the oocytes system: (Single-Channel Recording Second Edition 
(Book), Edited by Sakmann B. and Neher E., Plenum Press, 1995, USA)  
1. Hundreds of viable cells can be isolated from a given donor frog. 
2. The cells are quite hardy and can survive for up to 2 weeks in vitro.  
3. The cells are big (up to 1.3mm in diameter) and can be easily injected with RNA 
4. The oocytes faithfully express foreign RNA that has been injected into them.  
5. The oocytes have only a few endogenous channels (the major one being a Ca2+-activated 
Cl- channels) that are found in high density at the animal pole, and which usually carry only a 
small fraction of the current expressed. In voltage-clamp recordings, the Cl- current shows 
voltage-dependency, but this is a result of Ca2+ influx through endogenous voltage-gated 
Ca2+ channels followed by activation of the Cl- channels. The Ca2+ activated Cl- current can 
be inhibited by intracellular injection of Ca2+ chelators (BAPTA) or pharmacological blockers 
(Niflumic acid).  
Disadvantages of the oocytes system: 
1 Because of its large size, whole-cell patch-clamp experiments, where one can control the 
intracellular ionic compositions by dialysis across the patch pipette, are not possible. 
2. The endogenous channels, although few, can interfere with current measurements if they 
are small. 
3. Posttranslational modifications may be different in the oocytes compared with the native 
cells. Hence, channels may actually function differently in their native environment. 
4. Ocyte exhibit seasonal variation such that channel expression and ability to obtain seals 
are more difficult in the summer months. 
5. Xenopus is an amphibian, and the cells should be studied at room temperature (18-23°C). 
At higher temperatures, the cells rapidly deteriorate. 
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4.4. Voltage-clamp protocols used to characterize calcium channels 
 
4.4.1. Voltage dependence of activation 
 
Whole-cell Ba2+ current recordings 
The recording medium was a Ca2+- and Cl- free solution composed of (in mM): 40 Ba(OH)2, 50 
N-methyl-glucamine, 2.0 KOH, 5.0 HEPES, Niflumic acid (282mg/2l) pH adjusted to 7.4, 
with methanesulfonic acid. The voltage dependence of activation for HHT-α1C and RL-VSM-
α1Cb calcium channels was obtained by 350ms depolarizing pulses to different potentials 
from a holding potential of –60mV for the whole-cell measurements, –80mV for the TEVC 
experiments) at 15s. The exact holding potential used in the protocol is further specified in 
the results section. I-V curves were obtained by plotting the maximal current amplitude of 
every trace vs. voltage. I-V curves were fitted to standard Boltzmann equation in the form 
IBa= Gmax(Vm-Vrev)/(1+exp(-(Vm-V0.5)/K)), where K is the slope factor, V0.5 is the voltage that 
causes half maximal activation, Gmax is the maximal conductance, Vm is membrane voltage, IBa 
is the current measured at the same voltage , and Vrev is the reversal potential of IBa. In 
order to avoid the IBa run-down, we determined the I-V curves before and after drugs by 
using 80ms long test pulse from -50mV to +60mV from a holding potential at -80mV at 10s 
(0.1Hz).  In cardiomyocytes, ICa currents were activated by depolarizing steps (400ms) from 
-40mV to +50mV in 10mV increments from a holding potential of -50mV at 40s (0.025Hz) or 
5s (0.2Hz).  
 
Voltage dependence of steady state inactivation 
Steady-state inactivation was determined using a double pulse protocol: 5s prepulse to the 
various potentials from -80mV to +50mV at a holding potential of -80mV followed by a 30ms 
test pulse to –80mV. Finally a 400ms long test pulse was applied at +10 mV at 30s (0.033Hz). 
The normalized peak current at this potential is proportional to the percentage of calcium 
channels that are still available for activation. The data points were fit to a standard 
Boltzmann function: I/Imax=1/(1+exp[(V-V0.5)/kV]), with V0.5 being the voltage of half-
maximal inactivation and kV a slope factor. In cardiomyocytes, to measure the voltage 
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dependence of steady-state ICa inactivation, a gapped double-pulse voltage-clamp protocol 
was used. Ca2+ currents recorded at +10mV for 200ms after 1-s prepulse to increasing 
values of voltages between -80mV and +50mV at holding potential of -80mV at a frequency 
of 0.033Hz (30s). Channel availability was calculated by dividing the remaining current (I) at 
+10mV by Imax and expressed as a function of the prepulse potential.  
 
Inactivation time constants and persistent current 
The time course of decay for IBa in oocytes was determined using least-squares fit of the 
inactivating section of the current trace (5000ms) with a first exponential function by using 
the Chebyshev algorithm of Clampfit. C is the non-inactivating current. 
I(t)=A exp[-(t-t0)/τ] + C 
The amplitude A of the time constant τ contributes to more than 90% to the total current 
amplitude. 
 
Recovery from inactivation 
Recovery of IBa from inactivation was studied after depolarizing the calcium channels during 
a 3s prepulse to +10mV. The time course of IBa recovery from inactivation was estimated at 
a holding potential of -80mV by applying a 400ms test pulse to +10mV at various time 
intervals after the conditioning prepulse (from 20ms to 28s) at 30s.  After the double-pulse 
protocol oocytes were hyperpolarized to -100mV for 3min to permit the channels to recover 
from inactivation resulting in complete unblock of the channels. Peak IBa values were 
normalized to the peak current amplitude measured during the prepulse. The time course of 
recovery from inactivation was best fit to a second order exponential function with an initial 
delay. 
 
Use-dependent block 
Use-dependent block was determined as the inhibition of peak IBa during trains of 15 test 
pulses lasting 80ms applied at 0.5Hz from a holding potential of -60mV to test potentials 
+10mV positive to the peak potential of the I-V curves. An identical pulse protocol was used 
in the presence of drugs. Diltiazem (racemic) and the new Diltiazem analogs were perfused 
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in the bath (for a 3min period) at a concentration of 100µM. This concentration was 
selected because it provided sufficient block for the use-dependent measurements in 
Xenopus oocytes. In cardiomyocytes, basically the same protocol was used as for the 
oocytes, except in some experiment the test pulse was 320ms long under UDB protocol. 
 
4.4.2. Isolation of ventricular myocytes and electrophysiology 
Cardiomyocytes were dissociated from the ventricles of 4-5 month-old mice (FVB/n), by 
methods previously described [91]. Briefly, the heart was perfused with Ca2+-free Tyrode’s 
solution for 10 minutes, and with Ca2+-free Tyrode solution containing collagenase type 2 
(Worthington Biochemical Corporation, Lakewood, NJ, USA) and 1mg/ml BSA (Bovine Serum 
Albumin, fatty acid free) for 5-7 minutes by the Langendorff method at 37 oC. At the end 
of the perfusion, the heart was removed and the ventricles were mechanically 
disaggregated with a bore pipette. The dissociated cells were filtered through a nylon mesh, 
and stored at 4 oC in low Cl- high K+ Kraft-Bruhe (KB) solution (in mM): L-glutamic-acid 50, 
KCl 40, taurine 20, KH2PO4 20, MgCl2 3, Glucose 10, EGTA 1, HEPES 10, pH 7.4 with 1 M KOH 
until the electrophysiological (EP) studies. Only Ca2+ tolerant cells with clear cross striations 
and without spontaneous contractions or significant granulation were selected for the 
experiments.  
All current recordings were obtained in the whole-cell, voltage-clamp configuration of the 
patch clamp technique by using 1.60 OD borosilicate glass electrodes (Garner Glass 
Company). Cell capacitance was calculated by integrating the area under an uncompensated 
capacity transient elicited by a 25mV hyperpolarizing test pulse (25ms) from a holding 
potential of 0mV. Series resistance was within the range of 2 to 11MΩ. Most of the data 
presented in these studies were obtained with electrodes having a resistance of 0.5-3MΩ. 
After formation of a high resistance seal between the recording electrode and the 
myocytes membrane, electrode capacitance was fully compensated electronically before 
breaking the membrane parch. 
The recorded current (IBa) were filtered at 2KHz through a four-pole low-bass Bessel filter 
and digitized at 5kHz. The experiments were controlled using pClamp 5.6 software (Axon 
Instruments, USA) and analyzed using Clampfit 6.0.3. Ca2+ currents were recorded using an 
external solution containing (in mM): CaCl2 2, Tetraethyl-ammonium chloride (TEA- Cl) 135, 
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4-aminopyridine (4-AP) 5, glucose 10, HEPES 10, pH 7.3. The pipette solution contained(mM): 
cesium aspartate 100, CsCl 20, MgCl2 1, Mg-ATP 2, Na2-GTP 0.5, EGTA 5, HEPES 5, pH 7.3 
with 1 N CsOH. 
 
4.4.3. Statistics 
All data are shown as means±standard error of the mean (SEM) if not indicated otherwise, 
n=number of cells of animal tested. Comparisons between two groups were tested for 
statistically significant differences (p<0.05 or better) using a two-tailed unpaired Student’s 
t-test. Comparisons of amplitudes of IBa or ICa at different times (before and after drug 
application) in the same groups were done using a paired Student’s t-test. Comparisons 
between several groups was done using one-way analysis of variance (ANOVA) followed 
Turkey’s test. 
 
4.5. Isolated retrograde perfused heart preparation 
Mice were anesthetized intraperitoneally with a mixture of 8.7mg/ml Ketamine/1.3mg/ml 
Xylazine and injected with 1.5U heparin to prevent intracoronary microthrombi. The heart 
was rapidly excised, the aorta was canulated with a 20 gauge needle and perfused in a 
retrograde fashion at a constant hydrostatic pressure of 55mmHg with a modified Krebs–
Henseleit solution (KHS) containing (in mM): 118 NaCl, 4.7 KCl, 2.5 CaCl2, 1.2 MgSO4, 1.2 
KH2PO4, 25 NaHCO3, 0.5 EDTA 11 glucose. Buffer was equilibrated with 95% O2 and 5% 
CO2, insuring a pH of 7.4. Hearts were bathed in the perfusate in a water-jacketed bath 
maintained at 37.4 °C. A home-made fluid-filled catheter (PE-50) was inserted into the left 
atrium through the pulmonary vein, guided through the mitral valve opening, advanced into 
the left ventricle and forced through the ventricular apex. The proximal end of the 
catheter remained in the left ventricle. The distal end of the catheter was connected via 
fluid-filled polyethylene tubing to a further Baxter pressure transducer. Aortic pressure in 
the aortic outflow catheter was measured through a sidearm. A micrometer clamp was 
attached to the outflow catheter so that the Starling resistance (aortic pressure) could be 
monitored. Aortic flow was measured with a graduated burette in milliliters per minute. 
Coronary flow was allowed to drip from the pulmonary artery and measured by an electronic 
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balance to determine coronary flow rates. Following instrumentation, hearts were allowed to 
equilibrate for 30min. 
The performance of the heart was evaluated by analyzing the heart rate (HR, beats/min), 
the left ventricular pressure (LVP, in mmHg), which is an index of contractile activity and 
the mean coronary perfusion pressure were continuously monitored using a Biobench 
(‘National Instruments’) DAQ (Data Acquisition) system and digitized at 1kHz. The pressure 
curve was used to calculate the maximal values of the first derivative of LVP [(+dP/dt)max] 
(mmHg s-1), which indicates the maximal rate of left ventricular contraction, the maximal 
rate of left ventricular pressure decline of LVP [(−dP/dt)min] (mmHg s
-1), time to peak 
pressure (TPP) and time to half of relaxation (TR1/2) (s), which is the time required for 
intraventricular pressure to fall from peak to 50%. TPP and TR1/2 were normalized with 
respect to peak LVP since they are dependent upon the extent of pressure development. 
 
Drug infusion 
Identical dose–response curves were obtained by perfusing the heart with KHS containing 
increasing concentration (from 10-10-10-4M) of the Diltiazem and Diltiazem analogs in 2.0 mM 
[Ca2+]o. Drugs were added to the cardiac preparation entering the heart using a 
microperfusion pump (multispeed infusion pump, model 600, Harvard Apparatus). Hearts 
were exposed to each dose level for 150s for maximal response. Drugs were obtained from 
Sigma Chemicals (St. Louis, MO, USA). 
 
Statistical analysis 
Data are expressed as mean±S.E.M. Between groups statistical comparisons were made using 
the unpaired Student’s t-test. The statistical significance of the difference between 
control and serial hemodynamic changes within groups was determined by one-way ANOVA 
and multiple comparisons with the Turkey procedure. The differences in the dose response 
curves were analyzed by two-way ANOVA. p<0.05 was considered significant.  
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4.6. Isolation of adult cardiomyocytes for Ca2+ measurements 
Cardiomyocytes were isolated for analysis and only Ca2+-tolerant cells with clear cross 
striations and without spontaneous contractions or significant granulation were selected for 
experimental studies. In brief, the heart was rapidly excised and placed in Tyrode solution 
containing (in mmol/l): 120 NaCl, 5.4 KCl, 1.2 NaH2PO4,
 5.6 glucose, 20 NaHCO3, 1.6 MgCl2, 10 
2,3-butanedione monoxime (BDM), and 5 taurine (buffer A), gassed with 95% O2-5% CO2.
 All 
solutions were filtered and equilibrated with 95% O2-5%
 CO2 for at least 20min before use. 
The heart was retrogradely perfused with buffer A for 4–5min, then with buffer A 
containing 1mg/ml collagenase type II (Worthington, Freehold, NJ, USA) and 0.08mg/ml 
protease type XIV (Sigma) at 37°C. After 2min of enzyme perfusion, 50µM Ca2+ was added 
to the enzyme solution. When the heart became "swollen and soft" after 5min of digestion, 
the enzyme was recirculated. The heart was perfused for an additional 8–12min or until flow 
rate surpassed pre-enzyme flow rate. After perfusion, the ventricles were separated from 
the atria and minced. Myocytes were incubated with 2µmol/l Fura-2 acetoxymethyl ester 
(F-1221, Molecular Probes, Eugene, OR, USA) which was dissolved in dimethyl sulfoxide 
containing 0.02% pluronic acid (Pluronic F-127 20% solution in DMSO, Invitrogen, 
P3000MP)for 30–35min in buffer C (buffer A with 1mmol/l Ca2+ without BDM) at room 
temperature. After being loaded, the cells were washed and resuspended in buffer C. After 
three washes (40min), the cell suspension was placed in a plexiglass chamber containing 
500µl of fresh buffer C. The Fura-2 fluorescence ratio was determined at room 
temperature using a Delta Scan dual-bean spectrofluorophotometer (Photon Technology, 
Birmingham, NJ, USA), operating at an emission wavelength of 510nM with excitation 
wavelengths of 340 and 380nM. The stimulating frequency for Ca2+ transient measurements 
was 0.5Hz. Baseline amplitude (estimated by 340/380nM ratio) of the Ca2+ signal was 
acquired and data were analyzed using software from Felix 1.1 Software and IonWizard 
(IonOptix). 
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5. RESULTS 
 
5.1. Effect of Diltiazem and Diltiazem analogs on the characteristics of 
Ba2+ currents through L-VDCC 
 
The L-type calcium channels play a central role in the maintenance of cardiac and smooth 
muscle electrical and mechanical activity, and exhibit high affinity for the clinically useful 
drugs known as L-VDCC blockers (CCBs). Therefore, it is important to investigate the effect 
of the newly synthesized CCBs on both tissues. It is presumed that these new Diltiazem 
analogs might possess vascular sensitivity and perhaps differently regulate the 
electrophysiological and biophysical properties of the cardiac and smooth muscle L-VDCC. 
As previously discussed, CCBs have been shown to be powerful therapeutic tools in the 
treatment of a wide variety of disorders including hypertension, angina, and some forms of 
cardiac arrhythmias. From the therapeutic applications standpoint, the high degree of 
specificity of these drugs for smooth muscle L-VDCCs is very important. The DHPs are the 
most selective and potent CCBs and they have high vascular selectivity. However, in general, 
the vascular selectivity has a disadvantage: a reflex-adrenergic discharge with consequent 
tachycardia and positive inotropism which increases oxygen demand. A multidisciplinary 
project has led to a discovery of novel, structurally diverse benzothiazepine analog L-VDCC 
blockers. This project was developed and the primary results of the pharmacological and 
binding studies were performed in Bologna, Italy. The long term goal of this project is the 
continued studies of the new BTZ analogs which will provide new insight into the three 
dimensional structure of the BTZ binding site. At the beginning of the project a Ligand-
Based Virtual Screening (LBVS) procedure was developed in order to search for novel 
Diltiazem analogs. 340.000 molecules were screened, and selection was made based on 
selected criteria like molecular weight, etc. As a result, 20 compounds were tested in vitro, 
and functional experiments and binding assays revealed several promising compounds as 
potential Diltiazem analogs [92]. Therefore, the present study was designed to address 
whether the new Diltiazem analogs, (5b, M2, M7, M8 and P1), maintained the same 
biophysical and pharmacology properties as the Diltiazem on the L-VDCCs. We took 
advantage of the cloning and discovery of tissue-specific expression of the cDNAs for L-
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VDCC α1C subunits from human heart [84] and rabbit lung vasculature (VSM-α1Cb) [85]. In 
our experimental design, the effects of new Diltiazem analogs were extensively examined by 
electrophysiological and pharmacological methods. For the electrophysiological (EP) analysis 
the heterologous Xenopus oocytes expression system was utilized. The HHT-α1C/ or VSM-
α1Cb mRNAs were co-expressed with the auxiliary α2/δ and β3 subunits, and the current 
through the functionally expressed Ca2+ channels was measured. Based on a previous report, 
these experiments could provide evidence for the potential tissue selectivity of these 
selected Diltiazem analogs. Previously, Welling et al. [93] investigated the modulation of 
nisoldipine (DHP) on recombinant calcium channel activity in CHO (Chinese Hamster Ovary) 
cells stably transfected with α1 subunits of cardiac and smooth muscle L-VDCCs using patch 
clamp techniques. The paper focused on two aspects of the nisoldipine effect on cardiac and 
smooth muscle α1 channels. For comparison, native heart L-VDCCs: (1) tonic block at holding 
potential of -80mV and (2) the onset of the development of block at -40mV were tested. 
The results demonstrated that under identical experimental conditions the SM α1 channels 
were more sensitive to lower DHP concentrations that either native or recombinant α1 
cardiac channels.   
The authors speculate that the different IVS3 sequences and the presence of the 
alternatively spliced exon 8 within the IS6 segment [93] might contribute to the observed 
difference in DHP sensitivity. 
The Cav1.2 calcium channels in cardiac and smooth muscles have been shown to differ at 
four alternate spliced sites: (1) exon 1/1a in the N-terminus, (2) exon 8/8a, in the 
transmembrane segment IS6, (3) exon 9 in the cytoplasmic loop connecting domains I and 
II, and (4) exon 31/32 in the transmembrane segment IVS3. Notably, both channels share 
similar activation and inactivation properties [94,95]. In our experimental settings, Cav1.2 
α1Cb displayed a slight hyperpolarizing shift in steady-state inactivation potentials compared 
with Cav1.2 α1C (V0.5 -15.81±0.48mV and -12.04±0.69mV, respectively). It will be explained in 
detail later. Furthermore, the α1 subunit cloned from rat aorta by Koch et al. [96] is 93.9% 
identical to the α1 subunit from rabbit heart and does not contain the regions caused by 
splice variations in the lung.  Lately, Liao P. et al. [97] identified a new smooth muscle splice 
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variant which possess a biophysical property that can be linked to enhanced state-
dependent block by DHP. Exon 33 forms part of the IVS3-S4 linker region (Figure 10) and a  
previous study showed that the exclusion of exon 33 could shift the activation potential and 
steady state inactivation of Cav1.2 channels to a more hyperpolarized direction [98]. 
 
 
Figure 10. Amino acid (a.a.) alignment of various isoforms: human heart GenBankTM NM_000719 and rabbit 
smooth muscle GenBankTM X55763 are different at 3 sites. A schematic diagram of the Cav1.2 calcium channel 
shows exon1/1a (A), exon 9 (B) and Carboxyl-terminal (C). The positively charged S4 segments are the voltage 
sensors. The detailed localization of exons within motifs I-IV of HHT-α1C and Rabbit lung α1Cb further illustrated. 
Red boxes indicate the differences between the cardiac and smooth muscle form of Cav1.2 channel. Black box 
indicates the α-interaction domain (AID). 
H um an  h ea rt α1C ----------------- ------------MNANAAAGL APEHIPTPG  18
R ab b it Lu n g α1 MVNENTRMYIPEENHQG SNYGSPRPAHANMNANAAAGL APEHIPTPG  47
Hu ma n  he ar t α1 C DFQKLREKQQLEEDLKGYLDWI TQAEDIDPENEDEGMDEEKPRN--- 434
Ra b bi t l un g  a1 DFQKLREKQQLEEDLKGYLDWI TQAEDIDPENEDEGMDEEKPRNRGT  466
Hu ma n  he ar t a 1C ---------------------- MSMPTSETESVNTEN  449
Ra b bi t l un g  a1  PAGLHAQKKGKFAWFSHSTETH MSMPTSETESVNTEN  503
I II III IV
1 2 3 4 5 6 1 2 3 4 5 6 1 2 3 4 5 6 1 2 3 4 5 6
A.
B. C.
A.
B.
A ID
AID
Human heart α1C HGPPLSPAIRVQEVAWKLSSNRMHCCDMLDGGTFPPALGPRRAPPCL 1811
Rabbit Lung α1 HGSPLSPAIRVQEVAWKLSS--------------------------- 1838
Human heart α1C HQQLQGSLAGLREDTPCIVPGHASLCCSSRYGEWLPAGCTAPQHARC 1858
Rabbit Lung α1 --------------------------------------------KRC 1841
Human heart α1C HSRESQAAMAGQEETSQDETYEVKMNHDTEACSEPSLLSTEMLSYQD 1905
Rabbit Lung α1 HSQESQIAMACQEGASQDDNYDVRIGEDAECCSEPSLLSTEMLSYQD 1888
C.
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Native smooth muscle L-type Cav1.2 channels have more depolarized resting membrane 
potential than cardiac cells. Approximately 30% of Cav1.2 channels within rat aorta lacked 
exon 33, whereas over 95% of rat heart Cav1.2 calcium channels do express exon 33. Thus, 
the arterial smooth muscles contained at least two isoforms of Cav1.2 calcium channels: one 
is the traditional Cav1.2b, and the other is Cav1.2SM. To determine how such a small 
subpopulation of Cav1.2SM channels contribute sufficiently to vasotone, it will require 
additional work.   
It should be pointed out, however, that in patients suffering from Timothy’s syndrome, a 
mutation found in exon 8a of the Cav1.2 gene, which accounts for 11.5% of total Cav1.2 
channels, died from arrhythmias and sudden cardiac death [1].  
The present experiments compared the effects of Diltiazem analogs on HHT- and VSM-L-
VDCCs. EP protocols previously utilized in the oocytes expression system were applied to 
access the Ca2+-inhibiting characteristics of the new diltiazem analogs. The oocytes were 
injected with the designated mRNAs, and Ba2+ currents were measured using the “two 
electrode voltage clamp technique”. To eliminate Ca2+-dependent inactivation while 
measuring IBa, the external (recording) solution contained 40mM Ba
2+ as the charge carrier. 
Since α1C subunit was co-expressed with the auxiliary subunits, the expressed IBa peak 
current amplitude was around 4-6µA. Only oocytes expressing < 6µA of peak currents were 
used, this was to minimize errors originating from limitations of the two-electrode whole-
cell voltage clamp.  
At first the drugs’ effect was examined on the voltage-dependence of activation. To 
generate current-voltage relationships (I-V curve) of IBa, oocytes were held at a 
holding potential of -80mV and depolarized to voltages between -50mV and +60mV in 10mV 
increments for 400ms at 0.066Hz which allowed neither further accumulation of the use-
dependent block nor recovery from the blockade by Diltiazem at this holding potential.  
Depolarization was then discontinued, drug was applied, and after 3min quiescent period, 
depolarizing test pulses were resumed. I-V curves of wild-type HHT-α1C channels and VSM-
α1Cb are shown before and after drug application in Figures 11, 12. In 40mM Ba
2+ solution, IBa 
of the Wild-type HHT Cav1.2 activated at a threshold of -10 mV and reached peak current 
values between +10 and 20mV. The I-V curves did not show any statistical difference after 
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drug, compared with that of the absence of drug, with regard to the half maximum 
activation voltage (V0.5), the slope factor (K) and the peak current amplitude (IBa). 
Electrophysiological properties of the Diltiazem analogs and Diltiazem on the HHT Cav1.2 
channels compared with VSM Cav1.2 are summarized in Tables 3, 4, 5. The decrease in peak 
current amplitude was the most pronounced after application of P1, however, it fell short of 
statistical significance. In conclusion, none of the compounds, including Diltiazem produced 
any significant changes in the I-V curve of IBa at -80mV holding potential. The smooth 
curves are fit of the data to Boltzmann distribution. 
The results were similar using the VSM-α1Cb clone except the half activation potential (V0.5) 
was more hyperpolarized compared with those of HHT-α1C (-8.93±1.04mV vs. 4.12±1.35mV, 
respectively). However, some of the I-V curves displayed a hyperpolarizing shift (left) 
yielding a discrepancy compared with the presumed peak value (according to the literature) 
for the expressed Cav1.2 channels. This shift is most likely not due to the specific effect of 
the compound on the L-VDCC activation, but it is rather attributed to experimental 
technique like serious resistance error. When a current IBa flows across the membrane the 
resistance RS leads to a discrepancy between the measured membrane potential Vm 
(controlled by the amplifier) and the true potential difference across the membrane, Vt. 
The size of the error is IxRS. According to Ohm’s law, using this equation, it is possible to 
predict the distortion brought about by series resistance errors in the I-V curve. Series 
resistance errors can severely distort I-V curves. As a matter of fact, most of the times, 
since the transcript mRNA was very pure, oocytes expressed the Ca2+ channel very 
efficiently and it was extremely difficult to adjust the right timing for voltage-clamp 
measurements. In order to be able to record and measure such huge current (>6µA) without 
introducing error, it is important to use low- resistance electrodes (around 0.5MΩ) for both 
the voltage recording and current passing electrodes. The electrodes’ low resistance 
eliminates the need in a negative capacitance circuit, to correct for the frequency response 
of the voltage recording electrode, thereby removing this potential source of clamp 
instability. However, we could not completely exclude the possibility that the 
hyperpolarizing shift in some degree linked associated to the VSM-α1Cb clone. 
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Figure 11. Effect of 100µM of Diltiazem, M8, M2, P1, 5b and M7 on HHT-α1C (Cav1.2) channel.  Figure shows 
the current (I) -voltage (V) relationships for IBa before (black line) and after 3 min superfusion with Diltiazem 
(violet line), M8 (pink line), M2 (blue line), P1 (green line), 5b (red line) and M7 (orange line), respectively. Peak 
amplitude of Ba2+ current elicited by a 400-ms depolarization to the indicated test potentials (-50mV- +60mV) in 
10mV increments from a holding potential of -80mV is plotted against the test potential. Smooth line represents 
the best fit to a Boltzmann equation (See Methods). Each point and vertical bar represents the mean ± S. E. M of 
10-15 experiments. 
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Figure 12. Effect of 100µM of Diltiazem, M8, M2, P1, 5b and M7 on VSM-α1Cb (Cav1.2) channel. Figure shows 
the current (I) -voltage (V) relationships for IBa before (black line) and after 3min superfusion with Diltiazem 
(violet line), M8 (pink line), M2 (blue line), P1 (green line), 5b (red line) and M7 (orange line), respectively.  
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Voltage-dependent tonic block of Cav1.2 channels by Diltiazem and the newly 
synthesized Diltiazem analogs. After the beginning of whole cell recording, IBa amplitude 
was monitored until it was stable, with the use of 80ms test depolarizations to +10mV 
applied every 15s from a holding potential of -60mV. After the steady state has reached, 
the control was recorded using the same protocol as above except that the frequency was 
2s (0.5Hz). Drugs were then introduced into the bath at 100µM concentrations and IBa was 
recorded after 3min during this period of time to reach equilibrium. Tonic (“resting-state 
dependent”) block was defined as peak IBa inhibition during the first pulse after a 3min 
equilibration in drug-containing solution at the holding potential. It was previously mentioned 
that the interaction between Ca2+ channel blocker and the L-VDCC is modulated by the state 
of the channel (“modulated receptor hypothesis”) or by the transmembrane potential, thus, 
showing voltage-dependence, use-dependence or both. Application of the drugs produced 
little tonic block (Current inhibition % for diltiazem, M8, M2, P1, 5b and M7: -4.92±5.26; -
8.23±3.10; -10.13±2.66; -6.18±3.67; -3.01±1.87; -3.62±3.89, respectively) (Table 3, 4), 
indistinguishable from current “run-down” during a similar period in drug-free solution 
suggesting that these drugs hardly bind to the resting state of the channel (Figure 11, 12). 
Use-dependent block (UDB) by Diltiazem and Diltiazem analogs 
During repetitive depolarizations, block by PAAs and BTZs accumulates in a frequency or 
use-dependent and voltage-dependent manner because additional drug binds (association) 
during each depolarization and fails to unbind (dissociation) completely at the resting 
potential between depolarizations. Such a use-dependent block is important for the clinical 
efficacy of drugs. The use-dependent block develops more rapidly and more strongly at 
depolarized holding potentials, which is explained by the voltage dependence of dissociation 
rates of the drugs. To examine the UDB of IBa, trains of 15 pulses (80ms) applied from a 
holding potential of -60mV to +10mV (peak potential of the current-voltage relationship) at 
a frequency of 0.5Hz. The current amplitude for each pulse was normalized relative to that 
of the first pulse (Figure 17). The final steady-state block represents tonic block plus UDB. 
Diltiazem progressively decreased IBa in a use-dependent manner (Figure 13, 14, 15, 16 and 
17). M2, M8 and P1 did not show any use-dependency. We can see a slight decrease in IBa 
during the train due to the accumulation of inactivation. Based on these results, we might 
have expected a decreased current decay during the 3s test pulse by M8, M2 and P1, and 
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this could have explained in part the lack of use-dependency. Despite the significantly 
faster inactivation kinetics by the new Diltiazem analogs, UDB was not observed in oocytes 
injected with neither HHT-α1C nor VSM-α1Cb (Figure 14 and 17). 
Figure 13. Use-dependent block of Cav1.2 α1C channel currents. Use dependent IBa inhibition during fifteen 
consecutive test pulses by 100µM of Diltiazem, M8, M2, P1, 5b and M7, respectively. Depolarizing pulses (80ms 
duration) to +10mV test pulse from a holding potential of -60mV were applied at 0.5Hz frequencies. Mean reduction 
in peak current of IBa in each successive depolarizing pulse was normalized to that for the peak IBa during the first 
pulse and plotted against pulse number. The applied pulse protocol is displayed in the inset. Each point represents 
the mean of 13-18 experiments. 
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Figure 14. Use-dependent block of Cav1.2 α1C channel currents. 0.5Hz train consisting of fifteen 80ms 
depolarizations to +10mV was applied. Representative current traces of IBa, in the absence and presence of 100µM 
of diltiazem, M8, M2, P1, 5b and M7, respectively. The small decrease of IBa after application of M8, M2, P1, 5b and 
M7 shown in figure 14, is due to combination of the accumulation of voltage-dependent inactivation and “run-down” 
of IBa caused by the big current developed in the oocytes. 
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Figure 15.Use-dependent block of VSM-α1Cb (Cav1.2) channel current. Use dependent IBa inhibition during 
fifteen consecutive test pulses by 100µM of Diltiazem, M8, M2, P1, 5b and M7, respectively. 
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Figure 16. Use-dependent block of VSM-α1Cb (Cav1.2) channel currents. Representative current traces of IBa, in 
the absence and presence of 100µM of Diltiazem, M8, M2, P1, 5b and M7, respectively. The small decrease of IBa 
after application of M8, M2, P1, 5b and M7 shown in figure 16, is due to combination of the accumulation of 
voltage-dependent inactivation and “run-down” of IBa caused by the big current developed in the oocytes. 
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Figure 17.Use-dependent block of VSM-α1Cb (Cav1.2) channel currents. Use dependent IBa inhibition during 
fifteen consecutive test pulses by 100µM of Diltiazem, M8, M2, P1, 5b and M7, respectively. Depolarizing pulses 
(80ms duration) to +10mV test pulse from a holding potential of -40mV were applied at 0.5Hz frequencies. Mean 
reduction in peak current of IBa in each successive depolarizing pulse were normalized to that for the peak IBa 
during the first pulse and plotted against pulse number.   
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Action of Diltiazem and Diltiazem analogs on the time course of IBa 
To understand the reduction of frequency dependent block after the Diltiazem analogs in 
HHT Cav1.2 channels, the effect of Diltiazem and the Diltiazem analogs on Ca
2+ channel 
inactivation was examined. At first, from the sample traces of I-V relations, it was found 
that the voltage-dependent inactivation of HHT-Cav1.2 after M2, M8, and P1 was 
accelerated compared with that of control. To characterize the voltage-dependent 
inactivation of HHT-Cav1.2 after drugs, the time-dependent inactivation was analyzed.  
Hering et al. [81] suggested that inactivation is an important determinant for the 
development of use-dependent block by PAA. If Diltiazem interacts with calcium channels in 
their open state, the time course of IBa should be affected during a depolarizing voltage 
pulse, as has been described for calcium channel currents, when Ba2+ was the charge carrier. 
The effect of Diltiazem and the five Diltiazem analogs on the rate of current decay was 
determined during a maintained 3s depolarizations. Indeed, Diltiazem accelerated the rate 
of IBa decay during the depolarizing pulse. The drug-induced increase of the rate of IBa is 
caused by the development of drug block during the depolarization and is characteristic of 
the compounds that block the open and/or inactivated state of calcium channels that are 
present at depolarized potentials more potently than the resting state at -80mV. The 
inactivation process (descending phase of IBa) was fitted by mono-exponential curves with 
time constants of 269.11±12.97ms under control conditions and 207.23±10.05ms after 
exposure of 100µM Diltiazem. An unexpected finding was that M8, M2 and P1 significantly 
accelerated the time course of inactivation (See Table 6, 7, 8) in both HHT-α1C and VSM-
α1Cb channels. Treatment with 5b and M7 did not affect the time course of IBa significantly 
(Figure 18, 19 and 20).   
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Figure 18. Time course of Diltiazem and Diltiazem analogs block of depolarized channels.  Representative traces 
of Ba2+ current through HHT-Cav1.2 measured during 3s depolarization to +10mV from a holding potential of -80mV 
in the absence and presence of drugs. For each compound, the original recordings of IBa under control and under 
the influence of compounds were superimposed. In some cases, IBa was normalized to peak current, to facilitate 
comparison of the rate of current decay in the absence and presence of Diltiazem. 
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Figure 19. Time course of Diltiazem and Diltiazem analogs block of depolarized VSM-Cav1.2 channels current.  
For each compounds the original recordings of IBa under control and under the influence of compounds were 
superimposed. In some cases IBa were normalized to peak current, to facilitate comparison of the rate of current 
decay in the absence and presence of Diltiazem. 
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Figure 20. Voltage-dependent inactivation of IBa of HHT-α1C Cav1.2 channels (A, B, C), and VSM-α1C Cav1.2 
channels (D) (*, p < 0.05, **, p < 0.001, unpaired t test) evoked at test pulse of 10, 20, and 30mV for the HHT-
Cav1.2 channels and at test pulse of 10 mV for the VSM-Cav1.2 channels. Each column represents the mean ± SEM of 
the inactivation of IBa by Diltiazem (violet), M8 (pink), M2 (blue), P1 (green) 5b (red) and M7 (orange). 
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Effect of drugs on the steady-state inactivation of HHT-Cav1.2 channel 
To study the affinity of M8, M2, P1, 5b, M7 and Diltiazem for the inactivated state of the 
Ca2+ channels, the steady-state inactivation curves were determined using a standard 
double-pulse protocol. M8, M2, P1 and Diltiazem significantly shifted the steady-state 
inactivation curves towards the negative potential, suggesting that all of the drugs shift 
Ca2+ channels to the inactivated state (Figure 21, 22). From the Boltzmann’s distribution, 
V0.5 (the mid potential) and the K (slope of the curve) were calculated in the control 
condition and in the presence of 100µM of each six compounds including the reference 
Diltiazem. The V0.5 values are as follows: Control-1, V0.5=-12.04±0.69mV; Diltiazem, -
19.20±0.78mV; M8, -16.09 ± 0.98mV; Control-2, V0.5=-12.50±0.46mV; M2, -15.48±0.64mV; P1, 
-16.82±1.19mV (Tables 6, 7 and 8). Only M8, M2, 5b and M7 caused a slight change in the 
slope factor compared with control (Control-1, k=7.93±0.28 mV; M8, k=9.65±0.26mV; 
Control-2, k=7.38±0.27mV; 5b, k=8.17±0.12mV; M7, K=8.60±0.18mV). The finding is that 
three of the newly synthesized Diltiazem analogs M2, M8, P1 and the reference Diltiazem 
shifted the steady state inactivation curves to the hyperpolarizing direction, implying that 
these drugs have a higher affinity for the inactivated state of the channel than for the 
resting state.  
In the case of analysis of the steady-state inactivation, two different controls (since not 
every experiment after drug has self control), one for Diltiazem and M8, and another one 
for M2, P1, 5b and M7, were applied. The reason for that is the difference in the time of 
the measurements. In fact, at the beginning of the EP studies, the measurements were 
focused on the comparison between Diltiazem and M8 effects only, and later it was decided 
to include in the analysis the M2, P1, 5b and M7 compared with Diltiazem. During the latest 
set of experiments (new mRNAs were transcribed), IBa current and the number of 
experiments were bigger than during the first set experiments, so it was impossible to 
compare all compounds with Diltiazem and only one control for all of them. 
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Figure 21.Steady-state inactivation curves for IBa in the absence (black line) or presence of 100µM of 
Diltiazem (violet line), M8 (pink line), M2 (blue line), P1 (green line), 5b (red line), and M7 (orange line). Inactivation 
fraction was determined by using a two-pulse protocol in which a 5s conditioning prepulse to the indicated 
potentials was followed by a test pulse to peak IBa potential. Resultant currents were recorded before and 3min 
after superfusion with Diltiazem, M8, M2, P1, 5b and M7. The steady-state inactivation curves were obtained by 
normalizing the current values to the peak IBa at -80mV. The relative peak current at +10mV was plotted against 
the different prepulse potentials. Inactivation curves were fitted according to the Boltzmann equation (See 
Methods Section).  Each point and vertical bar represents the mean ± S.E.M. of 10-18 experiments.          
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Figure 22. VSM-α1Cb (Cav1.2) channel steady-state inactivation curves for IBa in the absence (black line) or 
presence of 100µM of Diltiazem (violet line), M8 (pink line), M2 (blue line), P1 (green line), 5b (red line), and M7 
(orange line).  
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Next we investigated the effect of Diltiazem and the five analogs on the time course of 
recovery of IBa from inactivation assessed using a standard two-pulse protocol. The 
recovery from inactivation induced by a 3s depolarization (prepulse) to +10mV from a 
holding potential of -80mV and it was measured using 350ms test pulses to +10mV after 
various intervals (25ms to 28s). Between the subsequently applied pulses trains the 
membrane voltage was held for 3min at -100mV, resulting in complete unblock of the 
channels (dissociation of the drug from its binding site). After returning to a negative 
potential following a voltage step, it takes a finite amount of time for the channels to 
recover from inactivation and be available to conduct for the next depolarizing pulse. Peak 
IBa, elicited by the test pulses were normalized with respect to the peak IBa of the prepulse, 
which should be constant. The fraction of current recovered is plotted against the recovery 
interval. The time course of recovery was well fitted with a double exponential equation 
(Figure 23, 24).   
Control and drug data were averaged from different groups of cells. As shown in Figure 23, 
recovery of HHT-Cav1.2 channels from inactivation in the absence of drug follows a 
biexponential time course, reflecting a fast and a slow time course of recovery from 
inactivation. In the absence of Diltiazem, the fraction of current was recovering with a fast 
(τf) and slow (τs) time constant of 48.98±4.20ms and 1823.74±221.71ms, respectively. In 
the presence of 100µM Diltiazem, the fast phase of HHT-Cav1.2 recovery is substantially 
slowed (τf=442.34±151.85ms) and the time constant of slow recovery is virtually unchanged 
(τs=1951.32±241.70ms). Slow recovery enhances the use-dependent block. These results are 
in good agreement with the data presented by Dilmac et al. [99]. However, the recovery 
from inactivation in 100µM M8 was not changed prominently compared with control. There 
was a slight difference in the fast time constant of recovery in presence of P1 (τf=94.14 ± 
17.97ms; τs=1350.73 ± 314.01ms) compared with control (Table 6, 7). The slow time constant 
was not significantly accelerated. The absence of use-dependent block of the Diltiazem 
analogs during pulse trains is probably due to an affect on channel recovery rather than 
causing decreased inactivation. Therefore, it allows fewer channels to bind since M2, M8 
and P1 accelerated the inactivation time in oocytes experiments. In summary, M8, M2, 5b 
and M7 did not show any relevant effects on the times of recovery from inactivation of the 
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channel. In the case of the VSM-α1Cb no difference was found with regard to time 
constants compared with results with HHT-α1C (Figure 24). 
 
 
Figure 23. Kinetics of IBa recovery from inactivation after treatment with Diltiazem and M2, M8 and P1. The 
time constant are summarized in Table 6, 7. The time course of recovery from inactivation at -80mV was 
determined by subsequent test pulses applied at various times (recovery interval) after the prepulse as described 
under “Methods”.  
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Figure 24. Kinetics of IBa recovery from inactivation of VSM-α1Cb (Cav1.2) channel, after treatment with 
Diltiazem and M2, M8 and P1. The time constant are summarized in Table 8.  
 
 
In all cases, recovery could be described by two phases. IBa rapidly recovered 
monoexponentially to 80-90% of control within 15s (termed “fast recovery”), and the 
remaining current which did not recover within the 15s period arbitrarily defined as “slow 
recovery” [100]. 
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Effects of Diltiazem and a novel Diltiazem analog M8 on mouse ventricular 
cardiomyocytes 
The aim of this study was to characterize the pharmacological effects of Diltiazem and M8 
on native cardiac Ca2+ channels, to check if the drugs actually function differently in native 
environment. It was assumed that the drug sensitivity on the cardiac calcium channel 
described in the oocytes system would be corroborated on cardiomyocytes. The whole cell 
configuration of the patch-clamp technique was used to measure ICa. From published data, it 
appears that in oocytes usually a five-to tenfold higher concentration of antiarrhythmic 
drugs are required to get an effect comparable with that of mammalian cell lines or native 
cells. It is possible that, the charged hydrophobic yolk in the intact oocytes complicate the 
drug equilibrium.  Furthermore, it was found that that the follicle cell layer surrounding the 
oocytes after incomplete digestion process can interfere with the drug effects drastically 
and can result in up to 30-fold increase in IC50 values, probably due to a reduced access of 
the substances to the oocytes membrane. Based on the results derived from the oocytes 
expression study effect of M8 was chosen to be studied on cardiomyocytes. Diltiazem and 
M8 were applied in concentrations of 10µM (corresponding to an intracellular concentration 
of ~100µM) in cardiomyocytes in 1.8mM Ca2+ containing recording solution. Diltiazem stock 
solution (10mM) was made in double distilled water, M8 (10µM) in dimethyl sulfoxide 
(DMSO) and this solution was used to make the appropriate dilution using the recording 
solution. Use-dependency was investigated using holding potential of -60mV, the same as in 
oocytes. We have to note that the development of UDB by Diltiazem is not simply 
dependent on the number of opening of channels (holding potential), but is dependent on the 
frequency and the duration of the test pulse. The results clearly show that block of Ca2+ 
channel current by Diltiazem can be modulated by changes in the duration of the test pulse. 
The effect of use-dependency after exposure of Diltiazem was most prominent when longer 
test pulse (320ms) was used in the train instead of the shorter pulse (80ms) (Figure 25). 
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Figure 25. Use dependent blockade of ICa. (A) Stimulation trains consist of 15 consecutive depolarizing voltage 
pulses were applied from a holding potential of -60mV to 10mV at 0.5Hz in the absence (control) and in the 
presence of Diltiazem and M8. The pulse durations were 80ms and 320ms, respectively. Trains were applied before 
and after a rest period of about 3min. at -60mV. ICa amplitudes were normalized to the amplitude of ICa elicited by 
the first pulse in a train. (B) Use-dependent peak ICa decay in the presence of Diltiazem and M8. Original current 
traces illustrating the use-dependent block during a pulse train in control and in presence of 10µM Diltiazem and 
M8. 
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The UDB was studied only at frequency of 0.5Hz under this EP protocol. Diltiazem 
suppressed ICa in a use-dependent manner without a significant tonic component (-4.6±4.1 % 
during 80ms pulse train and -7.4±5.2 % during 480ms pulse train,). It is clear from the 
representative figure that more channels are blocked when Ca2+, instead of Ba2+ is the 
charge carrier. Using both train pulses (80ms and 320ms), M8 produced a slightly bigger 
tonic block compared with Diltiazem (-10.9±3.5 % vs. -11.2±3.3 %, respectively). However, in 
good agreement with results obtained from oocytes, M8 failed to produce any use-
dependent inhibition on the ICa.   
In conclusion, these results with Diltiazem and M8 in cardiomyocytes confirmed the findings 
in heterologous expression system using the two electrode voltage clamp. 
It is a well known phenomenon that a train of repetitive depolarizations [101] drives the L-
VDCCs from their normal gating pattern into a mode of gating characterized by long opening 
and high open probability [102], a process that has been termed “facilitation”. The 
facilitation can be clearly seen in Figure 25. In cardiomyocytes, as a consequence of using 
Ca2+ as a charge carrier, calcium channels have evolved in the voltage and Ca2+-dependent 
inactivation mechanism. Therefore, in cardiomyocytes we have to take into consideration 
both inactivation processes. Both Ca2+ dependent inactivation and facilitation require high 
affinity binding of calmodulin (CaM) to the IQ motif (See Figure 1) located in the carboxyl 
terminal tail of the Cav1.2 channel [103]. Ca
2+ dependent facilitation has been attributed to 
the action of Ca2+/calmodulin-dependent protein kinase II.  
The effect of Diltiazem and M8 on ICa inactivation rate was also examined. As expected, M8 
revealed faster time and voltage dependent inactivation compared with that of Diltiazem.  
In contrast, Diltiazem in 10µM of concentration did not accelerate the Ca2+ channel 
inactivation [60,99]. The effects of Diltiazem and M8 on the voltage-dependence of the 
availability of L-VDCC are shown in Figure 26. The V0.5 of steady state inactivation was 
significantly shifted by -7.4mV. The slope factor between control and M8 are similar in 
steady-state inactivation (4.7±0.33mV vs. 4.8±0.03mV, respectively) [104].   
 
 
 
 
69 
 
 
Figure 26.Time course of Diltiazem and M8 block of depolarized wild-type Cav1.2 channels. (A) Representative 
traces of Ca2+ current through HHT-Cav1.2 channels measured during a 380ms depolarization from -60mV to +10mV 
in controls (black line) and after M8 (blue) and after Diltiazem (red), respectively. (B) Voltage dependence of 
inactivation in wild-type Cav1.2 channels. Peak Ca2+ current elicited by depolarization to +10mV immediately after 1s 
conditioning pulses to the indicated potentials from a holding potential of -80mV are plotted against the amplitude 
conditioning pulse voltage in the presence or absence of M8 and Diltiazem, respectively. 
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5.2. Langendorff hearts 
The present experiments aimed to elucidate whether the Diltiazem analogs in mouse hearts 
affect ventricular contractility (inotropism) and relaxation (lusitropic) within a wild range of 
concentrations. For this purpose we utilized the isolated mouse heart perfused according to 
Langendorff. The Langendorff system represents a good approach to analyze lusitropism 
and inotropism at the same time. This is because the ventricular systole occurs at isovolumic 
conditions; therefore the relaxation performance is not influenced by the contraction [105].  
Cumulative concentration-response curves (from 10-10 to 10-5M) of Diltiazem and the 
Diltiazem analogs were generated by exposing the cardiac preparations after taking 
baseline values to increasing concentrations of drugs.  Cardiac parameters were measured at 
2.5min. As seen in Figure 27 the negative inotropic effect of Diltiazem up to 10-6M was not 
statistically significant [106]. The observed relative sharp decrease after starting the drug 
perfusion process is considered an artifact due to switching to a perfusion pump therefore 
causing the perfusion pressure to decrease. Additionally, temporary temperature decrease 
could be also a factor and should be taken into consideration during the interpretation of 
the data. Usually, it takes 4-5min to stabilize the left ventricular pressure to the new 
setting in the perfusion rate. In retrospect, we should have begun the perfusion through 
the perfusion pump in addition to the retrograde perfusion with Tyrode solution and used 
these recordings as baseline values. Following administration of Diltiazem at 1µM, results 
were that the maximum rate of contraction (+dP/dt) showed only 6% reduction (from 
2541.32±111.0 to 2404.35±93.69 mmHg/s), whereas 10-5M caused sudden decrease in +dP/dt 
(1676.55±182.04 mmHg/s), probably due to the compound toxic effect on the heart.  M8, P1 
and 5b in the tested concentration ranges showed very similar tendency to Diltiazem 
regarding the effect on +dP/dt. M8 and P1 in 10-6M increased +dP/dt by 5%, however it was 
not significant (from 2703.84±122.31mmHg/s to 2859.76±261.29mmHg/s vs. from 
2826.25±74.24mmHg/s to 2955.65±181.82mmHg/s, respectively). Interestingly, M2 and M7 
displayed a statistically significant (p<0.05) increase in +dP/dt after both 10-6 and 10-5M 
concentrations. M2 caused a concentration-dependent increase (~10%) in +dP/dt which 
begun at a low concentration (10-9M) and persisted up throughout the higher doses (10-6 and 
10−5M). After perfusion of 10−6M M2 the +dP/dt increased from 2617.52±78.84mmHg/s to 
2910.87±104.42mmHg/s (p<0.05). M7 also induced a concentration dependent (~20%) 
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increase in +dP/dt, from 2709.55±114.56mmHg/s to 3139.25±144.26mmHg/s (p<0.05) in 10-
6M concentration. Original recordings before and after 1µM Diltiazem or the five Diltiazem 
analogs are shown in Figure 28.  
 
Figure 27. Concentration-response curves for  the effect of Diltiazem, M8, M2, P1, 5b, M7 (10nM to 10µM) in 
the isolated retrograde perfuse heart at 2mM [Ca2+] in the perfusion solution. +dP/dt was used as a indices of 
contractility and is displayed. Each symbol and vertical bar represents the mean ± S.E.M. (*, p < 0.05, **, p < 0.001, 
unpaired Student’s t-test). 
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Figure 28. Representative Intra Ventricular pressure traces before and after the exposition of the cardiac 
preparations to 1µM of Diltiazem, M8, M2, P1, 5b and M7. 
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Analysis of the myocardial effects of Diltiazem, P1 and 5b elicited a positive lusitropic 
effect, represented by a significant reduction in –dP/dt only in 10-5M concentration. After 
perfusion of M8, M2 and M7 a slight negative lusitropic (hastening) tendency was observed 
at the concentration tested, however, these variations were not significantly different 
from the control values in parallel with the change in dP/dt (Figure 29).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29. Concentration-response curves for  the effect of Diltiazem, M8, M2, P1, 5b, M7 (10nM to 10µM) in 
the isolated retrograde perfuse heart at 2mM [Ca2+] in the perfusion solution. -dP/dt was used as a indices of 
relaxation and is displayed. Each symbol and vertical bar represents the mean ± S.E.M. (*, p < 0.05, **, p < 0.001, 
unpaired Student’s t-test). 
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All of the compounds slightly decreased the heart rate in 10-5M and 10-6M concentrations, 
however only Diltiazem, P1 and 5b showed a significant decrease (Figure 30).  
 
Figure 30. Concentration-response curves for the effect of Diltiazem, M8, M2, P1, 5b, M7 (10 nM to 10µM) in 
the isolated retrograde perfuse heart at 2 mM [Ca2+] in the perfusion solution. HR was used as a indices of 
cronotropy and is displayed. Each symbol and vertical bar represents the mean ± S.E.M. (*, p < 0.05, **, p < 0.001, 
unpaired Student’s t-test). 
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5.2.1. Antiarrhythmic effect of Diltiazem and the selected Diltiazem 
analogs 
In addition to the hemodynamic measurements, we tried to access the antiarrhythmic 
effect of Diltiazem and the selected Diltiazem analogs in Langendorff–perfused mouse 
hearts. We took advantage of a transgenic mouse model which was previously developed in 
Dr. Schwartz’s laboratory [107]. In this transgenic mouse model, the L-VDCC HHT-α1C 
subunit was overexpressed (α1C-Tg) in a cardiac specific manner using the α-myosin heavy 
chain promoter. Increasing gene expression of the α1C subunit induces a sustained increase 
in [Ca2+]i causing significant changes in critical intracellular factors that trigger cardiac 
hypertrophy and eventual failure. The cellular electrophysiological changes include 
prolonged action potential duration, downregulation of potassium currents, and alterations in 
Ca2+ homeostasis. In general, sudden death occurrence could be due to ventricular 
arrhythmias associated with cardiac hypertrophy and failure. This is the result of 
remodeling processes that occurs in both the myocyte and interstitial compartments of the 
heart and creates a substrate that is vulnerable for triggering potentially lethal ventricular 
arrhythmias.   
Therefore, this α1C-Tg mouse model was utilized to investigate the possible antiarrhythmic 
property of two of the newly synthesized Diltiazem analogues, M8 and M2, compared with 
Diltiazem. It is well established that when this mouse model reaches 7-10 months of age, 
they develop cardiac hypertrophy associated with spontaneous ventricular extrasystoles, 
tachycardia or bradycardia. The arrhythmia occurrence was accessed from the left 
ventricular pressure. After recording the baseline conditions with “arrhythmia phenotype”, 
10µM Diltiazem, M8 and M2 were perfused, respectively. After drug (Diltiazem, M8 or M2) 
administration the persisting arrhythmia was suspended or completely suppressed. These 
preliminary experiments implicate that M8 and M2 have some antiarrhythmic effect despite 
the absence of use-dependency (Figure 31) since use-dependent-block is thought to be a 
particularly important mechanism of antiarrhythmic drug action. To further elucidate the 
antiarrhythmic aspect of the Diltiazem analogs is beyond the scope of this study and would 
require additional experiments.   
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Figure 31. Antiarrhytmic effects in transgenic hearts (HHT-α1C subunit over expressed) of 10µM M8 and M2, 
on Langendorff-perfused mouse hearts. 
Control 
Control 
After M8 
After M2 
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5.3. Electrically evoked cystolic Ca2+ transients in single cardiac mouse 
myocytes   
The previous experiments in the whole heart (Langendorff) indicated that M2 and M7 had a 
positive inotropic effect (+dP/dt). To correlate this finding on single cell level and provide a 
feasible explanation for the ex vivo results, the Ca2+ transients were measured in Fura-2 
loaded cardiomyocytes. Table 9 summarizes the effect of Diltiazem analogs compared with 
Diltiazem on the Ca2+ transients. In our analyses we were focusing on three parameters: the 
amplitude of Ca2+ transients (∆R 340/380), which was measured as the difference between 
diastolic and maximal systolic fluorescence ratio (∆R 340/380); TRC 50%, is time to 50% 
relaxation in [Ca2+]i and the time constant of recovery to baseline (τ). After adding 1µM 
Diltiazem to the perfusion buffer during continuous pacing, fluorescence ratio was 
significantly decreased by 16 % without changing TRC 50% and the τ. This result is good 
agreement with published data by others [108]. In contrast to Diltiazem, M8, M2 and M7 
produced a slight increase in the [Ca2+]i amplitude. This correlated with results generated 
from the ex vivo experiments (increased +dP/dt). During the present study we obtained 
supportive evidence (ex vivo and in vitro) that both M2 and M7, and in some instances M8, 
slightly increased the contractility at higher concentrations and was also accompanied by an 
increased decay of the Ca2+ transients (Table 9, Figure 32). One possible interpretation of 
this finding is that these drugs facilitate the coupling process between the L-VDCC and 
RyR-2 (increased EC gain). This process, called Ca2+-induced Ca2+ release (CICR) by A. 
Fabiato, causes a rapid increase in intracellular Ca2+ concentration to a level required for 
optimal binding of Ca2+ to troponin C and induction of contraction [8]. However, according to 
the electrophysiological measurements, these drugs did not increase IBa or ICa. The newly 
synthesized Diltiazem analogs might have an allosterical binding site beside the BTZ, or bind 
to an internal site producing increased levels of intracellular Ca2+. It is a known fact that 
Diltiazem is capable of stimulating the binding of dihydropyridines to T-tubular sites 
[92,109]. Interestingly, the action of DHPs can be related to the modulatory mode shift. In 
response to depolarization, the L-type channel opens. In the basal, unphosphorylated mode 
0, the probability of the channel being open is very low. Moderate phosphorylation, typically 
by stimulation of the β-adrenergic receptors, increases the probability of being open after 
depolarization (mode 1). More extensive phosphorylation leads to mode 2, where prolonged 
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channel openings occur, greatly increasing the current.  Mode 0 is also favored by binding of 
the Ca2+-antagonist drugs, and mode 2 is produced by agonist, for example BayK8644. “It is 
possible that the allosteric effects of phosphorylation are the reverse of those induced by 
drug binding, so they may bias the same molecular mechanism in opposite directions”  by H. 
Fozzard (Foundation of cardiac arrhythmias Edited by Peter M. Spooner & Michael R. Rosen, 
Marcel Dekker, Inc. 2001). In summary, our results are consistent with the idea that M2, 
M7 and M8 in lower concentrations have Ca2+-agonist effect without influencing the Ca2+ 
current through the L-VDCC. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 9. [Ca2+]i parameters in Fura-2 loaded cardiomyocytes. 
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Figure 32. Effects of Diltiazem and Diltiazem analogs on intracellular Ca2+ transients. Representative 
recordings of Ca2+ transients in response to field stimulation at 0.5Hz obtained from a myocyte before and after 
bath application of drugs.  
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6. DISCUSSION 
Previous studies showed that [1,4] thiazino[3,4-c] [1,2,4]oxadiazolones with a methyl group 
at position 5 of the thiazin-oxadiazolo ring, a free OH at C-8, and an unsubstituted or p-
bromo-substituted 8-phenyl ring exhibited negative inotropic potency [110]. In this context, 
a series of acetals were designed and functionally assayed, and the series of oxadiazolones 
were optimized with an ethyl group at position 8 (8-(4-bromophenyl)-8-ethoxy-8H-
[1,4]thiazino[3,4-c][1,2,4]-oxadiazol-3-one, coded as 5b) [111] (Figure 33). 
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Figure 33. Diltiazem structure compare with 5b structure, one of the Diltiazem structurally related compounds 
with a better negative inotropic potency than Diltiazem. 
 
However, important questions remained unsolved. Does 5b bind to the Diltiazem binding site 
or does it have its own site? Are both enantiomers of 5b active, or is only a single 
enantiomer active? Could 5b be used as a new template to search for novel calcium 
antagonists? 
First, to evaluate the stereoactivity of 5b, the two enantiomers were resolved by semi 
preparative enantio-HPLC. The absolute configuration of 5b was assigned using vibrational 
circular dichroism (VCD) spectroscopy. Second, assays on rat cardiomyocytes with [3H] 
Diltiazem as the radioligand were performed, and the direct interaction at the Diltiazem 
binding site was confirmed for 5b, although only at high concentrations. In addition, for 5b, 
the (-) isomer exhibited a more noticeable negative inotropic activity, demonstrating the 
stereo specificity of the binding site. Then, a ligand-based virtual screening (LBVS) 
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procedure was developed in order to search for novel chemotypes for calcium channel 
blockers, starting from the oxadiazolone series.  
The virtual screening procedure was based upon the oxadiazolone 5b and a database of 
approximately 340.000 commercially available compounds assembled in-house from 
commercial catalogues. 
Using different filters based on the selection of compounds with only C, H, O, S, N, P and 
halogens showing similarity in the active compound R(-) isomer 5b (i.e. similar  structure and 
molecular weight) and devoid of toxicity and instability, only 20 representative virtual hits 
were selected for purchasing and further investigation (Figure 34). 
 
Figure 34. Structures of Compounds Identified 
 Using Virtual Screening 
The pharmacological profile of all 20 compounds 
was tested on guinea-pig isolated left and right 
atria to evaluate their inotropic and chronotropic 
effects, respectively, and on K+-depolarized 
(80mM) guinea pig aorta strips to assess 
vasorelaxant activity. The results were compared 
with those of reference compounds Diltiazem and 
5b. Six out of 20 compounds (M7, M8, A2, A5, B2, 
P1) revealed a good inotropic profile, with negative 
inotropic EC50 values between 0.2 and 0.4µM. The 
structure of these compounds suggests that at 
least one bulky and lipophilic group is necessary for 
negative inotropic activity (i.e. the phenyl of A2, B3 
and M7; the azepine ring of A5; the 2-thienyl-pyrrolidine of M8; the cyclopropyl in tandem 
with the 4-piperydinyl substituent of P1). Six other compounds revealed an inotropic 
potency of the same magnitude as the reference Diltiazem (B4, B6, B2, M2, M5, A4), 
whereas all of the remaining compounds (A3, A6, M4, M1, M3, M6, Me, B5) have very low 
negative inotropic potency. 
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On the basis of parameters like the selectivity and negative inotropic potency, four 
compounds have been selected (M2, M7, M8 and P1) and analyzed together with 5b and 
Diltiazem, to investigate the affinity for the binding site of the latter (Figure 35). 
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Figure 35. Structures, inotropic EC50, chronotropic EC30 and vasorelaxant IC50 of Diltiazem and structurally 
related compounds (5b, M8, P1, M7, M2). 
 
Further functional tests were carried out for these selected compounds on isolated tissues 
(left papillary muscle) to assess the ventricular inotropic effect and isolated organs (guinea-
pig Langendorff perfused heart), to assess the cardiovascular profile. 
Since the Ca2+ channel antagonists also have important inhibitory effects on vascular and 
nonvascular smooth muscle, further investigations examined the relaxant activity of these 
selected compounds on K+ depolarized (80mM) guinea-pig ileum longitudinal smooth muscle.  
It is well-known that the Ca2+ influx may occur through two distinct pathways, one activated 
by membrane depolarization and the other by receptor-mediated events. The Ca2+ channel 
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antagonists appear to discriminate between these 2 processes, preferentially inhibiting 
mechanical responses of Ca2+ influx through the voltage-dependent Ca2+ channels (L-VDCC).  
For the newly synthesized Diltiazem analogs and the reference Diltiazem, the calcium 
channel antagonism was also determined as inhibition on the muscarinic receptor-mediated 
Ca2+-dependent contraction of guinea-pig ileum longitudinal smooth muscle, induced by the 
muscarinic agonist carbachol. 
 
Figure 36. Potency of Diltiazem, 5b, P1, M2, M7 and M8 in different guinea-pig preparations. 
 
M8 was characterized by high activity and potency on vascular and non vascular tissue of 
the same order as that of Diltiazem. In this group, M8 was the only compound showing 
vasorelaxant activity on both vascular and non-vascular smooth muscle similar to that of 
Diltiazem (Figure 36A). P1, M2, M7 and 5b possessed vasorelaxant effect only on non-
vascular smooth muscle (guinea pig ileum longitudinal smooth muscle) with lower potency 
than Diltiazem. P1 and M2 inhibited both the membrane potential and muscarinic receptor-
mediated Ca2+ dependent contraction. Interestingly, M7 and 5b showed vasorelaxant 
activity on non-vascular smooth muscle at lower potency compared with that of Diltiazem.  
M7 inhibited Ca2+ influx activated by membrane potential, while 5b inhibited Ca2+ influx 
caused by activation of muscarinic receptors.   
With regard to the positive inotropic and chronotropic effect of the selected compounds, 
three different guinea pig heart preparations were utilized (Figure 36B): (1) paced left 
atria for inotropy, (2) spontaneously beating right atria for chronotropy and (3) papillary 
muscle for ventricular inotropy. P1 displayed negative inotropic activity in paced left atria 
and papillary muscle, and in addition showed negative chronotropic potency similar to that of 
Diltiazem. M2, M7 and M8 showed negative inotropic effect both in left atria and 
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ventricular papillary muscle, and their potencies were higher than Diltiazem. The 
oxadiazolone 5b was found to have negative inotropic potency only in left atria. 
For the series of selected candidates, binding assay on rat cardiomyocytes was carried out 
in order to get information about their potential binding site. [3H]Diltiazem (5nM) was 
incubated with increasing concentrations (0.1nM-100µM) of the selected compounds to 
generate a dose-response curve.  
 
Figure 37. Effect of M2, M7, Diltiazem, 5b, P1 and M7 on 3[H]Diltiazem binding. 
 
Compounds 5b, M2, M7 and M8 affected the binding of [3H]Diltiazem, in a different 
manner. In fact, only P1 caused a concentration-dependent inhibition of [3H]Diltiazem 
binding. In contrast, 5b, M2, M8 and M7 revealed a complex interaction with the 
benzothiazepine binding site producing a small stimulation of [3H]Diltiazem binding at lower 
concentration, followed by partial inhibition at higher concentrations (Figure 37). The 
highest stimulation was observed with M8 (24.8% of control at 10nM), whereas the highest 
inhibition was displayed by M2 (59.6% at 100µM). 
P1 completely inhibited [3H]Diltiazem binding to rat cardiomyocytes, indicating a non 
benzothiazepine structure that can compete directly with Diltiazem at the benzothiazepine-
binding site. This is consistent with the effects produced by P1 on cardiac and non-vascular 
smooth muscle preparation where the molecule displayed the classical properties of a CCB. 
In addition, the minor effects displayed on vascular smooth muscle differentiated P1 from 
Diltiazem, suggesting that it might be classified as a unique CCB rather selective toward the 
cardiac tissue. The mixed pattern of modulation characteristics of the hits M2, M7, M8 as 
well as 5b is a preliminary indication that these compounds affect the benzothiazepine 
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receptor at low concentration by interacting at a distinct binding site, the occupation of 
which allosterically modulates Diltiazem binding in a positive manner. However, at higher 
concentrations, these molecules interact directly at the benzothiazepine binding site in the 
L-VDCC receptor complex [92].   
Using the Langerdorff perfused guinea pig heart, only Diltiazem showed a significant 
influence on the left ventricular contractile force (-59 ± 4.2mmHg/s), heart rate (-25 ± 
1.9beats/min), and coronary perfusion pressure (-51 ± 3.1mmHg).  
Having these previously published results in evidence, we tried to focus in our studies on 
techniques which were not utilized before in terms of characterization of the selected 
Diltiazem analog compounds. For the comprehensive electrophysiological investigation of the 
newly developed compounds, the Xenopus oocytes heterologous expression system was used, 
mainly since this system is well established and routinely used in Dr. Schwartz’s laboratory 
to study structure-function relationship of the L-VDCCs. Secondly, it is proven to be a very 
convenient system, relatively straightforward in terms of the technique and a good deal of 
valuable data can be generated within a year. Of course, as described in the “Methods” 
section in details, this system has advantages and disadvantages. One of the biggest 
disadvantages with respect to our study is that we were supposed to use a much higher 
concentration from the reference Diltiazem (and the newly synthesized compounds) than 
the therapeutic concentration which is in the single micromole range (Ref). However, we 
have to point out that the selected concentration of the BTZ Diltiazem used in our 
experiments is comparable with the concentration used by others, in many heterologous 
expression systems (both Xenopus oocytes and mammalian cell lines) and native cells (e.g. 
cardiomyocytes) [60,82,99,100,104,112-114]. It is well known that only the (+) cis-Diltiazem 
is the active enantiomer. In all of our experiments including the EP measurements, the 
racemic Diltiazem was used, commercially available from Sigma Chemical. In the Xenopus 
oocytes experiments, all of the compounds were applied in concentrations of 100µM for 
better comparisons with Diltiazem. 
We examined the new Diltiazem analog compounds including M2, M7, M8, P1 and 5b and 
compared them with Diltiazem using ex vivo and in vitro methodologies also.   
Ca2+ influx via voltage-dependent L-type Ca2+ channels (Cav1.2), found in cardiac and vascular 
smooth muscle, initiates contraction. Diltiazem, as the reference compound, is also used to 
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treat some types of supraventricular arrhythmias since it preferentially blocks channels 
that are activated at high frequency, a property known as frequency dependent block [115].  
In some complementary experiments we took advantage of a mouse model overexpressing 
the HHT-α1C subunit of the L-VDCC in mouse heart, which was developed in Dr. Schwartz’s 
laboratory in 1998. This mouse model offered both a physiological and pharmacological tool 
to test the potential antiarrhythmic property of two newly synthesized compounds since 
this transgenic mouse (named α1C-Tg) at 7-11 months of age (mo) develops cardiac 
remodeling with signs of arrhythmia. Overexpression of the α1C-subunit increases inward ICa 
and this would indirectly increase SR Ca2+ uptake, potentially to levels that could produce 
spontaneous SR Ca2+ release and causes arrhythmias as a consequence. The action potential 
duration was also prolonged in older mice resulting from a reduced transient outward 
potassium current (Ito) and the increased inactivation time of ICa, all of which can increase 
the likelihood of arrhythmogenic tendency. In younger mice when the heart performed 
better than wild-type due to early signs of the hypertrophy phenotype with overexpressed 
calcium channels, mostly spontaneous extrasystoles occurred but in older age the cardiac 
function became impaired (heart failure) and tachycardia combined with compromised 
atrial-ventricular conduction (e.g. bradycardia) appeared in many animals. The arrhythmia 
signs were reflected by the recording of the left ventricular pressure. The “pressure-
arrhythmia” incidence was around 50% in the α1C-Tg mice at 7-10 mo and lasted sometimes 
5-10min and thereafter returned spontaneously to normal sinus rhythm but in some 
instances, was continuous throughout the experiments (20min). Interestingly, perfusion of 
M2 and M8 to the Langendorff-heart reduced and in some cases completely suspended the 
incidence and the appearance of arrhythmia compared with those of DMSO-containing 
Tyrode solution perfused control group. However, this aspect of the study was not pursued 
in detail due to time limitations. The results are therefore considered to be preliminary and 
have been presented with caution. The observed “antiarrhythmic” effect of the two 
Diltiazem analogs is quite surprising since these compounds did not exert any use-
dependency and had very little tonic block on both IBa and ICa (however, it was significant 
for M8 and M2; around 10%). We have not investigated the effect of these drugs on action 
potential duration mediated by sodium and potassium channels at different phases of the 
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repolarization process and hence have no definite explanation for this effect. It is assumed 
that these compounds might have an inhibitory effect on Na+ or K+ channels or perhaps the 
moderate inhibition of ICa by M2 and M8 might contribute to their anti-arrhythmic action in 
the present model. 
The electrophysiological studies were performed in a heterologous expression system.  
Inward barium currents (IBa) (using 40mM Ba
2+ as the charge carrier) were measured using 
two microelectrode voltage-clamp of Xenopus oocytes 3-4 days after microinjection of 
mRNA mixtures of human α1C/β3/α2/δ [84] subunits. The voltage dependence and the 
kinetics of block by Diltiazem and M8 on L-VDCC (ICa) were investigated in mouse 
ventricular cardiomyocytes using the whole-cell patch clamp technique with 1.8 mM Ca2+ as 
charge carrier. The results, derived from the oocytes expression indicate that Diltiazem 
and the selected Diltiazem analogs in concentration of 100µM did not cause any substantial 
inhibition in IBa amplitude. Overall, there was no fundamental difference in the effect on 
the voltage-dependence of the I-V relationships between the selected compounds. The 
fitting yielded nearly identical values for either the half maximal potential or the slope 
factor.   
Conditioned (“use-dependent”) inhibition by Diltiazem is a characteristic property of L-type 
voltage dependent calcium channels. In the clinical setting, use-dependent drug action is 
therapeutically desirable property of the CCB antiarrhythmics. During repetitive 
depolarizations, the block by Diltiazem accumulates in a frequency and voltage-dependent 
manner because additional drug binds during each depolarization and fails to unbind 
completely at the resting potential between depolarizations. Such use-dependent block 
(UDB) is important for the clinical efficacy of the BTZ Diltiazem. As expected, IBa was 
efficiently blocked in a use-dependent manner by Diltiazem; in contrast, the selected 
Diltiazem analogs had no pronounced use-dependent block. In some recordings at 3 minutes 
(after perfusion with the compounds), progressive changes in Ba2+ currents were small and 
could be explained simply by combination of Ba2+ current “run-down” and the accumulation of 
Ca2+ channels in an inactivated state. Regarding the state-dependent Ca2+ channel block 
after exposure of the compounds, as stated above, very little change was observed except 
for M8 and M2. These compounds caused significant decrease in the peak IBa amplitude.   
90 
 
For comparison, and in order to confirm the results on native Ca2+-channels, EP 
measurements were performed on mouse cardiomyocytes using EP protocols similar to those 
used in oocytes. Using a lower concentration of Diltiazem (10µM) in cardiomyocytes for 
block of ICa through Cav1.2 channels, it is obvious that more channels are blocked with Ca
2+, 
rather than with Ba2+ as the charge carrier. However, results by Dilmac [99] suggest that 
Ca2+-dependent inactivation of Cav1.2 does not play a crucial role in the potentiation of 
Diltiazem block by Ca2+. In contrast, in the presence of M8, no use-dependence block was 
observed and the current amplitude at the 15th pulse was not significantly different from 
control. The results might imply that these compounds are somewhat different from 
Diltiazem regarding their binding properties. The classic calcium antagonist such as 
Diltiazem binds to the same site between transmembrane segments IIIS6 and IVS6 in both 
opened and inactivated conformational states of the L-VDCC, with the inactivated state 
having a higher affinity for Diltiazem. Of course, this hypothesis already has been proven 
by the binding experiments previously published by Carosati et al. [92]. The use-dependent 
block depends on many factors: membrane potential, frequency and duration of the test 
pulse. In mouse cardiomyocytes the prolongation of the test pulse from 80ms to 400ms led 
to a more rapid and profound steady level of use-dependent block after application of 
Diltiazem but use-dependency was still absent for M8. Also, both Diltiazem and M8 
produced slight tonic (resting-state-dependent) block in cardiomyocytes, however no 
significant differences were found in the mean values. The lack of appreciable tonic block 
indicates that the resting state has no significant affinity for these drugs. 
Calcium channel inactivation is an important determinant of use-dependent Ca2+ channel 
block by Diltiazem (BTZ) and Verapamil (PAA).  Hering et al. [81] were the first to suggest a 
close link between inactivation properties of the channel and use-dependent block by 
phenylalkylamines. Their data convincingly demonstrated that inactivation plays a key role in 
Ca2+ channel block by PAA. However, accelerated inactivation per se does not promote use-
dependent PAA block of chimeric channels lacking the high affinity determinants in IVS6. 
In cardiomyocytes, Lee et al. [115] found that faster inactivating Ca2+ currents are more 
efficiently blocked by PAA than slowly inactivating Ba2+ currents. In our experiments we had 
an unexpected finding: in spite of the diminished use-dependency by the new Diltiazem 
analogs, three compounds (M8, M2 and P1) accelerated the voltage dependence 
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inactivation in a time dependent manner. Comparatively, in Xenopus oocytes Diltiazem also 
accelerated the decay of the IBa current (inactivation time) during maintained step 
depolarization. We further calculated the time constant (τ values) with a single exponential 
equation. Effect of compound M8 on the voltage-dependent inactivation was also confirmed 
in cardiomyocytes. However, Diltiazem at a concentration of 10µM in cardiomyocytes did 
not show any effect on inactivation time despite its pronounced use-dependent block.  
According to the literature, Diltiazem displayed faster inactivation rate only in higher 
concentration even in the mammalian heterologous expression system using the enantiomer 
(+)-cis-Diltiazem [99]. The other feasible explanation for the discrepancy between the 
oocytes and native cells with regard to the effect of Diltiazem on the inactivation time of 
recombinant and native L-VDCC could be the co expression of HHT-α1C with the β3 subunit 
in oocytes. In heterologous expression system it is a well accepted procedure to co-express 
the auxiliary subunits with the pore forming α1C subunit to increase channel expression.   
It is well established that Cav1.2 inactivates in a Ca
2+-dependent and voltage-dependent 
manner. The rapid Ca2+ dependent component in the current decay is absent if Ba2+ served as 
charge carrier. The data by Dilmac et al. [99] suggest that Ca2+ dependent inactivation of 
Cav1.2 may involve Ca
2+ binding in the pore that is modulated by conformational changes in 
the C-terminal tail. Diltiazem preferentially inhibits the channel when it resides in or near 
the open and/or inactivated state however, the underlying mechanism of the tonic block may 
also include blockade of channels in resting state. Such preferential inhibition of 
open/inactivated states could underlie the substantial use-dependent component of block 
observed in Cav1.2 channels in presence of BTZs and PAAs. Many compounds that show use-
dependent block have an open-channel blocking action. The accelerated inactivation both in 
cardiomyocytes and oocytes after application of M8, M2 and P1 suggest that these drugs 
may act through blocking the open channels. However, we observed in cardiomyocytes, the 
Ca2+-dependent ICa facilitation which is characterized by a stepwise increase of ICa 
amplitude and a slowing of inactivation during train of repetitive depolarizations. It requires 
CaMKII-dependent phosphorylation, presumably of the α1C-subunit or an associated protein 
[116]. The facilitation did not interfere with the EP measurements since the use-dependent 
block by Diltiazem was very obvious. 
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In order to further determine the extent of inactivation of IBa or ICa a double-pulse 
protocol was applied. The steady state inactivation curves of wild-type (Wt) Cav1.2 channels 
before and after application of 100µM Diltiazem, M8,M2, M7, P1 and 5b were fitted to 
Boltzmann’s equation. Diltiazem, M2, M8 and P1 displayed a slight, but significant negative 
shift in steady-state inactivation potentials compared with control (before drug).  
Especially, in cardiomyocytes, perfusion with 10µM M8 induced a more profound shift in the 
V0.5 value compared to oocytes due to the use of Ca
2+ as a charge carrier instead of Ba2+.  
However, Diltiazem in a concentration of 10µM did not evoke significant change in the 
voltage-dependence of the availability of L-VDCC, in agreement with the unchanged 
inactivation decay of ICa at this concentration [115]. The finding that three newly 
synthesized benzothiazepine analogs caused a hyperpolarizing shift of the inactivation curve 
suggests that these compounds can interact with the inactivated channels in a special way.  
More importantly, the high affinity of M8, M2 and P1 (and Diltiazem) for the inactivated 
channels may cause these agents to act preferentially, on partially depolarized tissues in 
pathological conditions. Consequently, the potential reduction of Ca2+ influx under such 
conditions may contribute to a beneficial effect against arrhythmia.   
We have characterized the Diltiazem and the new Diltiazem analogs on the VSM-α1Cb 
channel expressed in Xenopus oocytes with a view to provide some information about the 
effect of the compounds on recombinant vascular smooth muscle Ca2+-channels. It is of 
interest that the VSM-α1Cb exhibited a slight left shift in its steady-state inactivation 
compared with that of HHT-α1C (-15.8mV vs. -12.0mV, respectively). This rather small 
difference is important given the fact that for the generation of vascular tone, the smooth 
muscle Cav1.2 channel activates at more hyperpolarized potential as already discussed in the 
“Results” section. Noticeably, the only biophysical difference found in our study, as 
mentioned above is that, the VSM-α1Cb channel inactivated closer to the resting potential 
compared with that of HHT-α1C. According to the functional profile studies performed and 
published with the new Diltiazem analogs by Carosati et al. [92], M8 had a vasorelaxant 
activity in guinea pig aorta strips with EC50 value of 5.62µM compared with that of 
Diltiazem 2.6µM. Based on these EC50 values, M8 is 2 fold less sensitive on vascular smooth 
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muscle Ca2+-channel than Diltiazem. Regarding the negative inotropic activity in left 
ventricular papillary muscle the EC50 values for Diltiazem and M8 were much different, 
0.11µM vs. 1.18µM, respectively. This is a clear indication that racemic compound M8 has 10 
fold less sensitivity to the ventricular L-VDCC compared with that of Diltiazem. In fact, 
based on our present results we do not have enough experimental evidence to delineate the 
contribution of Diltiazem and M8 to vascular and cardiac selectivity. Nevertheless, our 
results are somewhat consistent with the results published previously as no difference was 
found with regard to IBa inhibition through VSM-α1Cb Ca2+ channel after application of M2, 
M7, P1 and 5b. At the same time, there is some discrepancy with the previous results 
described on the rat aorta strips, because in our experiments as mentioned above, neither 
Diltiazem nor M8 (100µM) displayed any substantial tonic block on the VSM-α1Cb channel 
despite their effect on use-dependency/inactivation or both. The IBa block by Diltiazem and 
Diltiazem analogs in VSM-α1C channels, in many respects is quite similar to the state 
dependence of Diltiazem blockade with HHT-α1C channels. The discrepancy between our 
data and the published results may be due to the differences mainly in experimental 
conditions (like interspecies differences). First of all, we used recombinant channels instead 
of native channels. To be able to explain our findings on the Xenopus expression system we 
have to take into consideration several other factors. With an application time of 180 sec 
only acute effects can be studied. It is not absolutely sure that this perfusion time is 
sufficiently enough to induce all effects of the drugs. Therefore, it might be possible that 
due to problems in intracellular drug equilibrium, some of the described effects are not 
steady state and might increase at longer application time. However, to be able to increase 
the application time it would require an extremely good condition of oocytes and very good 
voltage clamp electrodes (to avoid clogging and damaging the oocytes). Based on the 
experience with the two-electrode voltage clamp on oocytes, it would require a tremendous 
amount of time and effort to comply with these two requirements. In addition, we have to 
take into consideration the Ca2+-induced Cl- current also in oocytes, when expressing Ca2+ 
channels. Therefore, before IBa measurements BAPTA is supposed to be injected into the 
oocytes in order to eliminate the Cl--current and avoid its interference with the IBa-
measurements. The other important issue as emphasized earlier is that oocytes require 
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much higher concentration of drugs to block ion channels than native cells. For example, 
single arterial vascular smooth muscle cells produced lower ICa amplitude in presence of Ca
2+ 
containing recording solution (>2mM Ca2+) compared with cardiomyocytes (or IBa in oocytes), 
and it is conceivable that such low ICa amplitude would enhance the effects of the drug. It 
will be interesting to check if differences in drug sensitivity of Cav1.2 (in heart and smooth 
muscle mRNAs) are related to a different subunit composition. Under physiological 
conditions the precise β-subunit composition of VSM-Cav1.2 is, however mostly unknown. 
Data from Colecraft et al. [51] suggests that β2b is a good candidate for the endogenous 
cardiac β-subunit.  As it was pointed out earlier, in our heterologous expression system, we 
have co-expressed the β3 subunit with both HHT-α1C and VSM-α1Cb. It is possible that 
using double concentration from the racemic Diltiazem or using the active enantiomer (+) of 
Diltiazem we would have quite likely been able to see an increase in IBa block and as well as 
to distinguish between Diltiazem and M8 in terms of “vascular selectivity” that was 
observed in rat aorta tissue. However, more detailed knowledge about the β-subunit 
composition of VSM-Cav1.2 is required before our data on the recombinant VSM-α1Cb Ca2+ 
channel can be correlated with pharmacological data obtained from native tissues. To 
address these problems the most potent Diltiazem analog compound should be investigated 
on native smooth muscle cells. 
Furthermore, we have to note, that no functional consequences associated with the VSM 
splicing variants were observed so far, with one exception. The DHP Nisoldipine produced a 
marked inhibition of recombinant smooth muscle [85] inward calcium channel current in CHO 
cells, as shown by Welling [93]. However, DHPs exhibit a high affinity for the VSM-α1Cb 
channels in the resting state. In a recent study, published in 2007, a novel smooth muscle 
Cav1.2 splice variant was reported (Cav1.2SM) that differs from the Biel et al. smooth 
muscle Cav1.2b [85] which was used for this study. The Cav1.2SM channel demonstrated a 
large hyperpolarizing shift in voltage-dependent inactivation and this gating property 
confers on the smooth muscle channel variant enhanced sensitivity to nifedipine compared 
with the Cav1.2b channel. In the future it would be interesting to test the effect of the 
novel compounds including the reference Diltiazem on this recombinant novel smooth muscle 
Cav1.2 splice variant.   
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Apart from the above discussed uncertainties and restrictions of our study on the oocytes 
expression system, in general, the present results reveal clear evidence and mechanism for 
drug effects on distinct calcium channel types.  
In order to clarify the voltage-dependence of the use-dependent effect of M8 and 
Diltiazem, recovery of IBa from inactivation was measured by use of a double-pulse protocol.  
Both the pre- and test- pulse were stepped to +10mV and the pulse interval was varied 
between 20ms-28s. The ratio of IBa obtained by the test pulse to that elicited by the 
prepulse (fraction of recovery) is plotted as a function of the interpulse interval. After 
returning to a deep resting state (-100mV) following a voltage step, it takes a definite 
amount of time for the channels to recover from inactivation and conduct for the next 
depolarizing pulse. In some of our experiments, the kinetics of the slow component of IBa 
recovery from block after Diltiazem could not have been resolved because contamination by 
current “rundown” during long lasting measurements could not be excluded. As we described 
above, the recovery could be described by two phases: IBa rapidly recovered mono-
exponentially to 80-90% of control within 10s (termed “fast recovery”), and the remaining 
current did not recover within the 10s period analyzed (termed “slow recovery”). From the 
total recoverable current, Kraus et al. [100] arbitrarily defined the contribution of “slow 
recovery” as the IBa not recovered after 15s. One model suggests that the channel opens on 
depolarization (state O) and then subsequently enters two inactivated states: I1 and I2. 
Two inactivated states were required to fit the bioexponential recovery from inactivation 
after 3s depolarization to +10mV, in the absence of drug. In this model, the rapidly 
recovering component arises from drug-bound open channels that are blocked during 
depolarizations and the slowly recovering component representing the drug bound 
inactivated channels. In the HHT-Cav1.2 channels, the slow recovery from block by Diltiazem 
was also predominantly caused by a slow rate of recovery of drug-bound, inactivated 
channels. The effect of Diltiazem resulted in a dramatic overall slowing of the recovery 
time course in wild type Cav1.2 channel. The unbinding rates suggest that Diltiazem bound to 
the channel receptors of open or inactivated channel more tightly and became trapped 
during the interval when the resting potential is held at -80mV. A delay in recovery from 
inactivation was previously observed for sodium channel inactivation and attributed to 
transition of channels to an additional (slow) inactivated state. Accumulation of sodium 
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channels in a slow inactivated state (for example by Lidocain) is induced by long lasting 
depolarization. The recovery from inactivation is described by exponential fit and the time 
constant for the recovery from the slow inactivated state ranging from several seconds to 
minutes.  By analogy to sodium channels, interaction with local anesthetics slow inactivation 
time which may have a very important role in the antiarrhythmic effect of Ca2+-antagonists. 
This delayed recovery was mainly due to an increase in the fast recovering component in 
good agreement with data by Dilmac et al. obtained on human tsA-201 (Human Embryonic 
Kidney) cells; however Diltiazem delayed the time course of the “slow recovering” 
component in some of our experiments which is also consistent with previous data [82]. 
Since Diltiazem promotes both fast and slowly recovering channel state, this explains the 
development of use-dependent block at a higher depolarization frequency [82]. It is 
believed that the time course of recovery from channel block is critically determined by the 
steric factors governing the rate of dissociation of the drug trapped within inactivated 
channel states. The size of the drug itself affects the rate of inactivation. Interestingly, 
the recovery from block by M8 was much faster than by Diltiazem, and it was comparable to 
control (absence of drug). In conclusion, our data demonstrate that the lack of use-
dependent block after application of M8, M2, P1 and M7 during pulse trains is probably due 
to a change in recovery from inactivation and not the decreased inactivation during test 
pulses, since we observed faster inactivation times allowing more channels to enter a drug-
bound state during the test train. The accelerated recovery from inactivation after M8 and 
M2 in Wild type Cav1.2 (HHT and VSM) channel compared to that of Diltiazem indicates 
either that these compounds have decreased binding affinity for the binding site or have 
more rapid dissociation rate from the binding site after being trapped in a blocked channel 
state.  Based on our EP data, it can be assumed that M8 has a steric structure that partially 
removes a dissociation barrier and facilitates dissociation of M8 from blocked (presumably 
open/inactivated) channel states. Therefore, we propose that the dramatic loss of use-
dependency after introduction of M8 is due to the rapid dissociation of the drug from the 
binding site since recovery from inactivation after drug application was comparable to 
control or even slightly faster (P1). 
The EP data also implies that M8, M2, M7 and 5b have a specific behavior and unique 
binding sites in close proximity and allosterically linked to the BTZ binding pocket and result 
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in a distinct effect from the classical representative benzothiazepine Diltiazem on L-
VDCCs. Our hypothesis, that the newly developed compounds allosterically modulate the 
BTZ binding site, is supported by the previously reported binding studies [92], confirmed 
and indirectly supported by our results in Langendorff-perfused mouse heart preparations 
as well as in calcium transient measurements on isolated mouse ventricular cardiomyocytes.  
M8, M2, M7 and 5b produced a stimulatory effect on [3H]Diltiazem binding at low 
concentration which was converted to an inhibitory at higher concentration. This finding 
correlates well with our results that some of the newly developed Diltiazem analogs 
produced biphasic effect ex vivo and in vitro: In lower concentrations (1µM or less), they 
evoked positive inotropic effect and at higher concentration this declined.  
 “The Ca2+ antagonistic potency of bezothiazepines is critically dependent on the presence 
of two pharmacophores, i.e., the basic amino group in ethyl linkage at position N-1 and 
hydrogen bond acceptor (preferentially a methoxy group) at position 4’ on the 4-aryl ring. 
The affinity of BZT also increases with their hydrophobicity, indicating partitioning into a 
hydrophobic environment. This suggests that the benzothiazepine binding domain consists 
of a hydrophobic pocket that accommodates the hydrophobic substituted benzothiazepine 
ring next to a polar region that interacts with the basic amine“[63]. 
Taken together, our data convincingly show that the new Diltiazem analogs especially M8, 
M2 and P1 accelerated the inactivation decay of both recombinant Ca2+ channels in the 
Xenopus oocyte expression system and in cardiomyocytes without developing any evidence 
for use-dependent block which is very characteristic of the Diltiazem. The experiments 
described here suggest that depolarization of the membrane and opening of the channels 
were required for Diltiazem and the other Diltiazem analogs to exert their blocking action.   
 
7. Limitations of the study future plans and final conclusion 
In this study five newly developed Diltiazem analogs were systematically characterized and 
compared with the reference Diltiazem with regard to their inhibition on two classes of Ca2+ 
channels (cardiac α1C and vascular smooth muscle α1Cb) expressed in Xenopus oocytes and 
native mouse cardiomyocytes. In complementary experiments, we studied the effect of 
these compounds on the cardiac performance using Langendorff perfused mouse hearts and 
98 
 
on Ca2+ transients in isolated mouse cardiomyocytes. Previous data revealed several 
important properties of these compounds [92]. Among them, the [3H]Diltiazem binding data 
provided strong indication that M8, M2 and M7 have a very specific profile resembling the 
characteristics of DHPs with respect to their positive allosteric modulation at the 
benzothiazepine binding sites. The dihyropyridine Ca2+ channel blockers are allosteric 
modulators and may act on the L-VDCC as either agonist favoring the open state or 
antagonist favoring inactivated state. The typical organic Ca2+ channel blockers including the 
DHPs, PAAs and BTZs bind to distinct, allosterically coupled, high affinity binding domains 
on the α1 subunit of the L-VDCC (motifs IIIS6 and IVS5). During this study, independent 
lines of evidence confirmed this hypothesis: in lower concentrations (up to 1µM) some of 
these compounds elicited positive inotropic effect ex vivo accompanied with slight, but 
significant increase in Ca2+ transients in fura-2 loaded cardiomyocytes. An attempt was 
made to further elucidate the detailed mechanism of the interaction of these drugs with 
their receptor sites on recombinant Ca2+-channels using electrophysiological measurements.  
Together with previous pharmacological and drug binding data the electrophysiological 
results generated in this study, provide some insight into the molecular mechanism that 
underlies the regulation of Ca2+ channel gating by these compounds.  
Considering the restrictions of the oocyte system, our findings suggest that these 
compounds exert significant effect on channel inactivation but lack the use-dependent 
effect that is very characteristic of the BTZs. UDB is a “hallmark” of the antiarrhythmic 
activity. We used Diltiazem as a reference drug for comparison which exerts UDB 
associated with slowed recovery from inactivation process. During the use-dependency 
protocol, blocked channels accumulate because of incomplete recovery of drug-bound 
channels during diastole. The slowed recovery of drug bound channels can be explained by 
combination of the modulated receptor hypothesis [78,79] and the guarded receptor model 
[117]. The modulated receptor hypothesis proposes that antiarrhythmic drugs like Diltiazem 
have higher affinity for their binding sites during activated and inactivated gating states of 
the Ca2+ channel. Therefore, the unbinding of the drug and consequently, the recovery of 
the drug-bound channels is slowed down. The guarded receptor model emphasizes that the 
drug appears to bind to the channel protein when it assumes a specific conformation.  
Furthermore, based on this model, “the state-dependent availability of the drug access path 
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to and from their binding sites influences the binding and unbinding kinetics” [118]. Our 
findings with the Diltiazem analogs suggest that there must be other distinct structural 
elements in repeats III and IV, different from the amino acids most critical to Diltiazem 
binding (Y1490, A1494, I1497), that are involved in the drug effect. The existence of a 
physically distinct binding region controlling drug binding and access to the receptor fits 
naturally with a guarded receptor mechanism of drug inhibition.   
According to our results the Ca2+-channel block by Diltiazem and the new Diltiazem analogs 
on VSM-α1Cb Ca2+ channels in Xenopus oocytes was quite similar to that of HHT-α1C Ca2+ 
channels. The novel Diltiazem analog M8, M2 and P1, like Diltiazem, have little tonic block 
(significant block was observed only after application of M8 and M2), but accelerated the 
inactivation of IBa. These results are interpreted as resulting from the higher affinity of 
the drug for the open and inactivated Ca2+ channels.   
In contrast, no change in the inactivation time constant of ICa was observed after Diltiazem 
was exposed in isolated mouse cardiomyocytes. It has been described for PAAs that the 
amount of block of cardiac ICa was dependent on the duration of a preceding depolarization.  
For Diltiazem, the blockade of inactivated channels may be particularly important because 
open channel block is not prominent even at the relatively high concentration of 50µM under 
certain experimental conditions. We superfused the cardiomyocytes with 10µM Diltiazem in 
the patch clamp experiments. In oocytes expression, M8, M2 and P1 significantly shifted 
the steady-state inactivation curves toward negative potential, suggesting that these 
compounds shift the Ca2+-channels to the inactivated states as also observed with Diltiazem.  
In correlation with the unchanged inactivation time after Diltiazem exposure in 
cardiomyocytes, the steady-state inactivation curve was overlapped with the curve 
generated before drug.  Diltiazem exhibited a slower recovery from inactivation in oocytes 
suggesting that this drug can interact with the inactivated channels with a slow dissociation 
rate. In contrast, M8, M2 and P1 demonstrated a fast recovery from inactivation which is 
possible due to the fast dissociation of these drugs from the Ca2+ channels, allowing the 
drug to dissociate before the next depolarizing test pulse is given. In general, drugs with 
very fast time constant of recovery have a very small effect on and block the calcium 
channel for too little time. Hondeghem named the type of antiarrhythmic drugs that showed 
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fast recovery from block “No effect” drugs. These agents “might provide ideal competitive 
displacers to treat an overdose” [119]. The other possible explanation for the fast recovery 
from inactivation, which is comparable with control, is that these newly synthesized 
compounds shift the Ca2+ channel into a rapidly recovering inactivated state. This hypothesis 
is partially supported by the fact that these drugs abolish use-dependent effect. Since M8 
and M2 caused the biggest tonic block on recombinant cardiac Ca2+ channels, it is attractive 
to speculate that these compounds might exert some vasorelaxant effect. However, in our 
experimental design, no significant differences were obtained among the compounds using 
the VSM-α1Cb compared with those of HHT-α1C L-VDCCs. The explanation for that is quite 
complex and it was elaborated on this issue in the “Discussion” section. One feasible 
explanation for that is the importance of the L-VDCC subunits. Increasing evidence 
indicates that the drug sensitivity is affected by the composition of subunits in different 
expression system. The possibility that the same auxiliary subunits were coexpressed with 
the different α1 subunits cannot be excluded and this contributed to our results. It would 
have been interesting to compare the biophysical properties of the novel smooth muscle 
Cav1.2SM splice variant with the HHT-α1C channel using the new Diltiazem analogs and 
Diltiazem applying the same EP protocols as in the present study. According to Liao et al. 
[97] data, the Cav1.2SM channel demonstrated a large hyperpolarized shift in the voltage 
dependent inactivation curve and the gating property, modeling the native vascular smooth 
muscle L-VDCC. However, the relevance of Cav1.2SM channels to the function of the smooth 
muscle in vessels requires additional proof but can potentially be used as a tool in future 
studies. However, due to the uncertainties of the oocytes expression system detailed in the 
“Methods” section, the most reliable information about the vasoselectivity and the gating 
properties of the novel compounds could be derived from experiments using native smooth 
muscle cells.   
Some calcium channel blockers also have other mechanisms of action, such as interaction 
with α-adrenoreceptors, inhibition of intracellular Ca2+ release or influx of Ca2+ through 
receptor operated calcium channels [120]. The pharmacological properties of some Ca2+ 
channel blocking compounds are consistent with those of Diltiazem and Verapamil. These 
experiments are out of the scope of this study. These newly developed Diltiazem analogs 
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could extend our knowledge about the three dimensional structure of the benzothiazepine 
binding sites of the L-VDCCs. However, we can not be positive with regard to the potential 
clinical aspect of their usage.   
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